Effects of bifunctional chemotherapeutic agents on gene expression in the human tumor cell line Colo320HSR by Dong, Qing
Loyola University Chicago 
Loyola eCommons 
Dissertations Theses and Dissertations 
1993 
Effects of bifunctional chemotherapeutic agents on gene 
expression in the human tumor cell line Colo320HSR 
Qing Dong 
Loyola University Chicago 
Follow this and additional works at: https://ecommons.luc.edu/luc_diss 
 Part of the Molecular Biology Commons 
Recommended Citation 
Dong, Qing, "Effects of bifunctional chemotherapeutic agents on gene expression in the human tumor cell 
line Colo320HSR" (1993). Dissertations. 3014. 
https://ecommons.luc.edu/luc_diss/3014 
This Dissertation is brought to you for free and open access by the Theses and Dissertations at Loyola eCommons. 
It has been accepted for inclusion in Dissertations by an authorized administrator of Loyola eCommons. For more 
information, please contact ecommons@luc.edu. 
This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 3.0 License. 
Copyright © 1993 Qing Dong 
LOYOLA UNIVERSITY CHICAGO 
EFFECTS OF BIFUNCTIONAL CHEMOTHERAPEUTIC AGENTS ON GENE 
EXPRESSION IN THE HUMAN TUMOR CELL LINE COL0320HSR 
A DISSERTATION SUBMITTED TO 
THE FACULTY OF THE GRADUATE SCHOOL 
OF LOYOLA UNIVERSITY CHICAGO 
IN CANDIDACY FOR THE DEGREE OF 
DOCTOR OF PHILOSOPHY 
PROGRAM IN MOLECULAR BIOLOGY 
BY 
QING DONG 
CHICAGO, ILLINOIS 
May 1993 
Copyright by Qing Dong, 1993 
All rights reserved. 
ii 
DEDICATION 
To my husband, Fengdao Liu, for his unconditional love, 
understanding and support. 
To my parents, Huijie Jiang and Yaping Dong, for their 
belief in me and their encouragement. 
iii 
ACKNOWLEDGMENTS 
I would like to thank my advisor, Dr. Leonard Erickson, 
for his guidance and financial support which made this 
dissertation possible. Many thanks to my committee members 
Ors. Thomas Ellis, Mark Kelley, Celeste Napier, Sullivan Read, 
and Jerome Seidenfeld for their commitment to and interest in 
my dissertation project. 
I am grateful to Dr. Russell O. Pieper for his efforts to 
help me both in thinking as a scientist and in learning 
English as a second language. I am indebted to Dr. Bernard w. 
Futscher for his help in setting up some early experiments. 
I wish to thank Dr. Roger A. Kroes, for his input in 
experimental design and his time in making all the slides and 
photographs for this dissertation. I would also like to thank 
Ms. Nancy Hora and Mr. Nick Vlahos, for their friendship and 
help which made my initiation at the lab enjoyable. 
Special thanks to Mrs. Pamela Erickson, Ms. Fran Jannece 
and Mr. Chaohong Yu for their patience in reading this 
dissertation and ensuring its grammatical correctness. I 
would also like to thank Dr. Youlian Liao for his help in 
statistical analysis of the data. 
iv 
VITA 
The author, Qing Dong, was born in Hubei, China, on May 
4, 1963. 
The author received her M.D. degree from Tongji Medical 
University in July, 1983. After graduation, Ms. Dong worked 
as a resident in Internal Medicine for three years in the 
First Teaching Hospital of Tongji Medical University. 
In March, 1986, Ms. Dong started her research career as 
a research assistant in the Department of Pathology at 
Northwestern University, sponsored by a fellowship provided by 
the Chinese government. 
In August, 1987, Ms. Dong received a basic science 
fellowship and began her doctoral studies in the Program in 
Molecular Biology at the Medical Center of Loyola University 
Chicago. The author was also awarded a Dissertation 
Fellowship in 1992. Ms. Dong is an associate member of the 
American Association for Cancer Research. 
Ms. Dong has accepted a position as Research Associate in 
Preuss Laboratory for Brain Tumor Research at Duke University 
in Durham, North Carolina. 
V 
DEDICATION 
ACKNOWLEDGMENTS . 
TABLE OF CONTENTS 
iii 
iv 
VITA . . . . . . . . . . . . . . . . . . . . . 
LIST OF FIGURES. 
LIST OF TABLES 
LIST OF ABBREVIATIONS. 
INTRODUCTION 
V 
ix 
xii 
. . . xiii 
REVIEW OF RELATED LITERATURE . . . . . • . . . 
Oncogenes is . • . . . . . . . . . • .•. 
DNA Cross-linking Agents .....•....... 
Heterogeneous DNA Damage and Repair .•. 
Colo320HSR Cell Line. . . ......... . 
The c-myc Oncogene. . . . ....... . 
A. The c-myc Gene Structure ........ . 
B. The c-Myc Protein ........... . 
C. Regulation of c-myc Expression ... . 
D. Oncogenic Activation of the c-myc Gene 
GAPDH Gene . . . . . . . . . . . . . . . . • . . . 
c-fos Oncogene . .............. . 
Histone H3.3 Gene 
8-actin gene ...............•. 
MATERIALS AND METHODS . ............. . 
Cell Culture ........ . 
Reagent Preparation ...........•. 
I. DNA Cross-linking Agents ... 
II. General Chemical Agents. 
Drug Treatment . . . . . . . . . . . . . . . . . . 
Colony Formation Assays ............ . 
General Methods ................ . 
I. Nucleic Acids Isolation ...... . 
A. Plasmid DNA Isolation ....•... 
i). Large Scale Preparation of 
Plasmid DNA .....•. 
ii). Small Scale Preparation of 
vi 
1 
4 
4 
6 
11 
14 
15 
16 
18 
21 
22 
24 
25 
27 
28 
29 
29 
30 
30 
30 
31 
32 
33 
33 
33 
33 
Plasmid DNA . . . . . . . . . 35 
B. Total Cellular RNA Isolation . • . . 36 
C. Genomic DNA Isolation. . . . . . . . 37 
II. Nucleic Acid Quantitation. . . . 38 
A. Spectrophotometric Quantitation of DNA 
or RNA . . . . . . . . . . . . 38 
B. Minigel Method . . . . . . . . . 39 
III. Purification and Concentration of DNA 39 
IV. Agarose Gel Electrophoresis . . . . . . 40 
A. DNA Agarose Gel Electrophoresis. 40 
B. RNA Agarose Gel Electrophoresis. . . 41 
V. Nucleic Acid Blotting. . . . . . . . . . 42 
VI. Filter Hybridization . . . . . . . . . . 43 
VII. Filter Stripping and Reprobing. . . . . 44 
VIII. Autoradiography. . . . . . . . . . 45 
IX. cDNA Synthesis . . . . . . . . . . . 45 
X. DNA Dot Blot. . . . . . . . . . . . . 45 
XI. DNA'sequencing . . . . . . . . . . . 46 
Preparation of DNA probes . . . . . . . . 47 
I. General Information . . . . . . . 47 
II. DNA Subcloning . . . . . . . . . 48 
A. Isolation of DNA Fragments from 
Agarose Gel . . . . . . 50 
B. BAP reaction . . . . . . . . . . 50 
c. Ligation . . . . . . . . . . 51 
D. Transformation . . . . . . . . . 51 
III. 32P-Labeling of Hybridization Probes 52 
IV. Quantitation of 32P Incorporation 53 
Polymerase Chain Reaction . . . . . . . . 54 
Northern Blot Analysis. . . . . . . . . . . . 57 
DNA Denaturing/Renaturing Gel Electrophoresis and 
Southern Blot Analysis . . . . . . . . . . . 58 
Nuclear Run-on Analysis . . . . . . . . . . . 60 
RESULTS • . • • . . • . . . . . . • • . . • . . 63 
Cytotoxicity Studies. . . . . . . . . . . . . 63 
DNA Damage and Repair Studies . . . . . . . . 63 
Effects of DNA Cross-linking Agents on Gene 
Expression Studies . . . . . . . . . . . 64 
Normal Fluctuation of c-myc mRNA . . . . . . 73 
Effects of Cisplatin and HN2 on Gene 
Expression at the mRNA Level . . . . 74 
Effects of Cisplatin and HN2 on Gene 
Expression at the Transcription Level 75 
Total RNA Synthesis and Cell Proliferation 76 
Studies on Accessibility of Individual Genes to DNA 
Damage Induced by HN2. . . . . . . . . . . . 76 
Changes in mRNA Levels of the c-myc, c-fos and 
GAPDH Genes in Colo320HSR Cells after 
Serum Starvation. . . . . . . . . . . . 97 
The Relative Transcription Rates of Genes in 
vii 
Colo320HSR Cells ........... . 
Formation of DNA Interstrand Cross-1 inks at 
the Gene Level in Exponentially Growing 
Cells . . . . . . . . . . . . . . . . . 
Formation of DNA Interstrand Cross-links at 
the Gene Level in Cells in Stationary 
Phase . . . . . . . . . . . . . . . . . 
Formation of DNA Interstrand Cross-links at 
the Gene Level in Cells Treated with 
Hydroxyurea . . . . ....... . 
DISCUSSION 
DNA Interstrand Cross-link Formation 
Disappearance in Individual Genes ...• 
Suppression of c-myc mRNA Expression Mediated at 
and 
the Transcriptional Level ......... . 
studies on the Accessibility of a Gene to HN2-
induced DNA Interstrand Cross-linking Damage 
Regulation of c-myc and GAPDH Gene Expression 
References 
viii 
98 
99 
100 
101 
119 
119 
122 
124 
126 
130 
LIST OF FIGURES 
Figure Page 
1. Chemical structures of cisplatin and nitrogen 
mustard . . . . . . . . . . . . . . 8 
2. The c-myc gene structure and its transcripts. . 17 
3. Maps of plasmids containing the subcloned specific 
gene fragments . . . . . . . . . . . . . . . . . 4 9 
4. Nucleotide sequence of c-fos and histone H3.3 PCR 
primers 
5. Schema for measuring DNA interstrand crosslinks in 
genes 
. 55 
. 59 
6. Survival of Colo320HSR cells following exposure to 
various concentrations of cisplatin for 1 has 
determined by inhibition of colony formation .... 65 
7. Detection of cisplatin-induced DNA interstrand 
cross-links in the c-myc oncogene immediately after 
1 h drug exposure . . . . . . . . . ...... 66 
8. Disappearance of cisplatin-induced DNA interstrand 
cross-links formed in the c-myc oncogene ..•... 68 
9. Disappearance of DNA interstrand cross-links after 
cisplatin treatment in Colo320HSR cells .. 72 
10. Changes of the steady state c-myc mRNA levels in a 
mock experiment assessed by northern blot analysis. 77 
11. Inhibition of the steady state c-myc mRNA levels 
following 1 h cisplatin exposure as detected by 
northern blot analysis ............... 79 
12. Inhibition of the steady state c-myc mRNA levels 
after 1 h HN2 treatment measured by northern blot 
analysis . . . . . . . . . . . . . . . . . . . . . . 81 
13. Nuclear run-on analysis of in vitro transcription 
ix 
in isolated Colo320HSR nuclei following 1 h 
cisplatin exposure ............•... 85 
14. Nuclear run-on analysis of in vitro transcription in 
isolated Colo320HSR nuclei following 1 h HN2 
treatment . . . . . . . . . . . . . . . . . . . 8 7 
15. comparison of c-myc transcription rates and mRNA 
levels after 1 h cisplatin treatment ..•..... 89 
16. comparison of c-myc transcription rates and mRNA 
levels after HN2 exposure . . . . . . . . • . . 91 
17. Experimental design for studies on accessibility of 
a gene to DNA damage induced by HN2 .....•. 102 
18. Northern blot analysis of changes in c-myc, c-fos, 
and GAPDH mRNA levels after serum starvation in 
Colo320HSR •...••..•.......•.. 103 
19. Nuclear run-on analysis of in vitro transcription 
in isolated Colo320HSR nuclei after serum 
starvation . . . . . . . . . . . . . . . . . . . 105 
20. Production of HN2-induced DNA interstrand cross-
links in the c-myc, c-fos, and GAPDH genes in 
exponentially growing Colo320HSR cells detected by 
DNA denaturing/renaturing gel electrophoresis and 
Southern blot analysis. . .......... 106 
21. Formation of HN2-induced DNA interstrand cross-
links in the c-myc, GAPDH, c-fos genes after serum 
starvation measured by DNA denaturing/renaturing 
gel electrophoresis and Southern blot analysis .. 108 
22. Comparison of changes in c-myc transcription and 
DNA interstrand cross-linking formation in the 
c-myc gene induced by HN2 in Colo320HSR cells 110 
23. Comparison of changes in GAPDH transcription and 
DNA interstrand cross-linking formation in the gene 
induced by HN2 in Colo320HSR cells. . ..•. 112 
24. Northern blot analysis of changes in the steady 
state c-myc mRNA levels after hydroxyurea 
treatment . . . . . . . . . . . . . . . . . . 114 
25. Nuclear run-on analysis of in vitro transcription 
in isolated Colo320HSR nuclei after hydroxyurea 
treatment . . . . . . . . . . . . . . . . . . . . 116 
26. Production of HN2-induced DNA interstrand cross-
X 
links in the c-myc and GAPDH genes in Colo320HSR 
cells after hydroxyurea exposure detected by DNA 
denaturing/renaturing gel electrophoresis and 
Southern blot analysis .........•.... 117 
xi 
LIST OF TABLES 
Table 
1. Effects of cisplatin on c-myc mRNA levels 
2. Effects of HN2 on c-myc mRNA levels 
Page 
. 83 
. 84 
3. Incorporation of a-32P-UTP after cisplatin exposure 93 
4. Incorporation of a-32P-UTP after HN2 exposure . 94 
5. Colo320HSR cell concentration after cisplatin 
treatment . 95 
6. Colo320HSR cell concentration after HN2 treatment . 96 
xii 
µCi 
µg 
µl 
µM 
APS 
BAP 
bp 
cisplatin 
cm 
CM 
cpm 
ddNTP 
DEPC 
DHFR 
DM 
DMSO 
dpm 
ds 
DTT 
EDTA 
EGF 
LIST OF ABBREVIATIONS 
microcurie 
microgram 
microliter 
micromolar 
ammonium persulfate 
bacterial alkaline phosphatase 
base pair(s) 
cis-diamminedichloroplatinum (II) 
centimeter 
conditioned medium 
counts per minute 
2',3'-dideoxyribonucleoside 
acid 
diethyl pyrocarbonate 
dihydrofolate reductase 
double minute 
dimethyl sulfoxide 
disintegrations per minute 
double stranded 
dithiothreitol 
5'-triphosphate 
ethylenediamine tetraacetic acid 
epidermal growth factor 
xiii 
FM 
g 
GAPDH 
h 
HEPES 
HN2 
HSR 
HU 
IPTG 
kb 
L 
lb 
M 
mci 
mg 
min 
ml 
mm 
mM 
mmol 
mRNA 
N 
ng 
nt 
OD 
fresh medium 
gram 
glyceraldehyde-3-phosphate-dehydrogenase 
hour(s) 
N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic 
acid 
mechlorethamine, nitrogen mustard 
homogeneously staining region 
hydroxyurea 
isopropylthio-B-D-galactoside 
kilobase(s) 
liter 
pound 
molar 
millicurie 
milligram 
minute(s) 
milliliter 
millimeter 
millimolar 
millimole 
messenger RNA 
normal 
nanogram 
nucleotide(s) 
optical density 
xiv 
PBS 
PCR 
pmol 
rpm 
RPMI 
rRNA 
SDS 
sec 
sq. in. 
ss 
SSC 
TBE 
TCA 
TE 
TEMED 
Tris 
u 
UV 
v/v 
w/v 
X g 
oc 
phosphate-buffered saline 
polymerase chain reaction 
picomole 
revolutions per minute 
Roswell Park Memorial Institute 
ribosomal RNA 
sodium dodecyl sulfate 
second(s) 
square inch 
single stranded 
standard saline citrate 
Tris-borate-EDTA buffer 
trichloroacetic acid 
Tris-EDTA buffer 
N,N,N',N'-tetramethylethyl-enediamine 
Tris-[hydroxymethyl)-aminomethane 
unit(s) 
ultraviolet 
volume per volume 
weight per volume 
times gravity 
degrees Celsius 
xv 
INTRODUCTION 
cancer arises when abnormal cells in the body multiply 
without restraint and produce a group of descendants that 
invade surrounding tissues. The molecular basis underlying 
cancer development has not been completely clarified. 
However, increasing evidence has shown that cancer is a result 
of an accumulation of multiple genetic alterations, which 
involve activation of oncogenes and inactivation of tumor 
suppressor genes. 
The treatment of cancer depends on surgery, chemotherapy, 
radiotherapy, and immunotherapy. Chemotherapy plays an 
important role in the treatment of cancer by utilizing several 
groups of cytotoxic chemical agents. The predominant 
mechanism by which some cytotoxic drugs exert their toxicities 
generally is thought to involve DNA damage. Prior to 1980, 
most of our knowledge regarding DNA damage and repair was 
gained under the assumption that these events occur in the 
genome randomly. Recent advances in the study of DNA damage 
and repair at the gene level reveal a heterogeneity of these 
processes in mammalian cells. Little information is known 
regarding the interaction between DNA damaging anti-tumor 
1 
2 
agents and individual genes, and changes of gene expression in 
response to DNA damage. 
The goal of this dissertation is to elucidate the 
relationship between DNA damage and repair at the gene level, 
and alterations of gene expression in response to DNA damage 
induced by the DNA cross-linking agents, HN2 (mechlorethamine, 
nitrogen mustard) and cisplatin (cis-diamminedichloroplatinum 
(II), cis-Pt). The hypothesis that DNA cross-linking agents 
(HN2, cisplatin) preferentially produce DNA interstrand cross-
links in transcribed genes and suppress their expression was 
investigated. Attempts were made to address the following 
questions: 
*** Are DNA interstrand cross-links induced by HN2 or 
cisplatin detectable at the gene level? 
*** Is oncogene expression suppressed by either HN2 or 
cisplatin? 
*** Is the transcriptional state of a gene correlated 
with its accessibility to HN2-induced DNA damage? 
This study was carried out in a human tumor cell line 
(Colo320HSR), which harbors an amplified and overexpressed c-
myc oncogene. The effects of HN2 and cisplatin on c-myc gene 
expression was studied in order to reveal responses of an 
activated oncogene to DNA cross-linking agents. The GAPDH 
gene served as a control gene because it is a single copy 
3 
number gene and presumably constitutively expressed. The c-
fos gene, which is silent in exponentially growing Colo320HSR 
cells, was used as the control in HN2-induced DNA interstrand 
cross-linking experiments. The histone H3.3 and B-actin genes 
served as constitutively expressed controls for gene 
expression studies. Different control genes were used in each 
set of experiments due to the measurability of each gene in 
different assays. 
The effects of the DNA cross-1 inking agents, HN2 and 
cisplatin, on gene expression were 
transcriptional and steady state 
assessed at both the 
mRNA levels. The 
accessibility of a gene to HN2-induced DNA interstrand cross-
links was correlated with its relative transcription rate. 
REVIEW OF RELATED LITERATURE 
oncogenes is 
It is becoming increasingly clear that tumor formation 
arises as a consequence of alterations in the control of cell 
proliferation and differentiation. Some of these control 
points have been identified and have undergone intensive 
investigation. Multiple genetic changes observed in tumors 
support the concept that oncogenesis must be a multi-step 
process. The genetic changes found in tumor cells are of two 
types: induction, such as the activation of proto-oncogenes; 
and suppression, such as the inactivation of tumor suppressor 
genes. 
Cellular proto-oncogenes encode proteins that play an 
essential role in normal biochemical processes with three main 
sites of action: the cell-surface membrane, the cytoplasm, and 
the nucleus (Bishop, 1987; Weinberg, 1985). Approximately 60 
oncogenes have been identified to date, including genes 
encoding growth factors (e.g., sis, int-2, hst), receptor and 
nonreceptor protein-tyrosine kinases (e.g., src, erbB, neu), 
membrane-associated G proteins (e.g., ras, gsp, gip), 
cytoplasmic protein-serine kinases (e.g., mos, pim-1), and 
nuclear transcription factors (e.g. myc, fos, jun) (Varmus 
4 
5 
l989; Hunter, 1991). The activation of proto-oncogenes 
involves a variety of mechanisms, resulting in either 
overexpression of a normal cellular protein, or the expression 
of an altered form of a normal cellular protein. For 
instance, the c-myc proto-oncogene is activated in many tumors 
by overexpression of the normal protein (Hayward et al., 1981; 
Alitalo et al., 1983; Perry, 1983; Leder et al., 1983). The 
product of ras oncogenes also can transform cells when point 
mutation occurs in their alpha subunits (Bourne et al., 1990). 
Mutations in codon 12, 13, or 61 of one of the three ras 
genes, H-ras, K-ras, and N-ras, convert these genes into 
active oncogenes (reviewed in Bos, 1989). 
Transformation of a normal cell also is facilitated by 
recessive 
suppressor 
regulation 
mutations of certain genes. These are tumor 
genes whose products are involved in negative 
of cell proliferation. In contrast to the 
oncogenes discovered, only a small number of tumor suppressor 
genes have been identified to date. Known tumor suppressor 
genes include the Rb gene in retinoblastoma (Lee et al., 
1987), WTl gene in Wilms' tumors (Rose et al., 1990), p53 gene 
in various tumors (Rotter and Prokocimer, 1991; Hollstein et 
al., 1991; Levine et al., 1991), DCC and MCC genes in 
colorectal carcinoma (Fearon et al., 1990; Kinzler et al., 
1991a), and APC gene in familial adenomatosis polyposis 
(Kinzler et al., 1991b). Although much remains to be learned 
about the function of each tumor suppressor gene, it is clear 
6 
that loss of the normal function of these genes is important 
in tumorigenesis. 
In general, the current model for loss of normal cellular 
growth control includes inactivation of one or more tumor 
suppressor loci inhibiting proliferation, and/or activation of 
one or more oncogenes to give a positive signal for 
proliferation (Marshall, 1991). The cooperation of two or 
more oncogenes and tumor suppressor genes appears to be 
required for tumorigenic transformation (Land et al., 1983; 
Hunter, 1991). 
DNA Cross-linking Agents 
Chemical cross-linking agents include the nitrogen and 
sulfur mustards (Brookes and Lawley, 1961), nitrosoureas 
(Ludlum et al., 1975; Kohn, 1977), mitomycin C (Iyer and 
Szybalski, 1963), and various platinum derivatives (Roberts 
and Pascoe, 1972), and certain intercalating furocoumerins 
(e.g. 8-methoxypsoralen) in a photocatalytic reaction (Cole, 
1970) . These agents form covalent cross-links between the two 
complementary strands of DNA, which may pose a block to DNA 
replication or RNA transcription. HN2 and cisplatin are among 
the most efficacious DNA cross-linking anti-tumor agents in 
chemotherapy (Kohn, 1983). These agents were chosen as the 
drugs for this study because of their common ability to 
produce DNA interstrand cross-links. 
7 
Nitrogen mustard was the first nonhormonal agent to show 
significant anti-tumor activity in humans (Gilman and Philips, 
1946). The discovery of anti-tumor activity of HN2 led to the 
development of a wide variety of anti-tumor agents clinically 
used today, and HN2 remains a major drug used in the treatment 
of lymphoma. 
The presence of the bis-(2-chloroethyl) group makes HN2 a 
highly reactive electrophilic compound (Figure 1) . HN2 
produces a wide spectrum of DNA lesions, including 
monoadducts, intrastrand adducts, and interstrand cross-links 
(Colvin, 1982). HN2 alkylates primarily at the N-7 position 
of guanine (Mattes et al., 1986 and 1988; Kohn et al., 1987 
and 1988; Hartley et al., 1988), and interacts in GC-rich 
regions to form DNA interstrand cross-links (Brooks and 
Lawley, 1961; Kohn et al. , 1966; Chun et al. , 1969) . Al though 
HN2 can form covalent linkage (alkylation) with various 
nucleophilic moieties, the presence of two chloroethyl groups 
is required for its anti-tumor activity, suggesting that DNA 
cross-links are effective lesions (Kohn et al., 1966; Chun et 
al., 1969; Mattes et al., 1986). 
Platinum complexes were discovered serendipitously by 
Rosenberg in the early 1960s due to their ability to inhibit 
bacterial division (Rosenberg et al., 1965). Cisplatin 
(Figure 1) was found to be active against a wide variety of 
tumors, such as head and neck, cervical, testicular, and 
ovarian carcinomas (Roberts and Thomson, 1979; Rosenberg, 
NH3'-. /Cl 
Pt 
NH3/ '-c1 
cis-Pt HN2 
Figure 1. Chemical structures of cisplatin and nitrogen 
■ustard. 
8 
1985; Sherman and Lippard, 1987). 
9 
Cisplatin also forms 
monoadducts, intrastrand adducts and interstrand cross-links 
in DNA. The major lesions of cisplatin are d{GG) and d{AG) 
1,2-intrastrand adducts (Sherman and Lippard, 1987; Eastman, 
1987) . DNA interstrand cross-links represent less than 10% of 
total adducts, which are preferentially formed at the d{GC) 
sites {Lemaire et al., 1991). 
Extensive studies have shown that DNA interstrand cross-
linking induced by HN2, or cisplatin, plays an important role 
in cell killing. Direct evidence for the presence of DNA 
interstrand cross-links was provided by a number of physical 
techniques, including velocity sedimentation studies and 
denaturation-renaturation studies (Brooks and Lawley, 1961; 
Horacek, 1971). In addition, the DNA alkaline elution method 
has provided a very sensitive assay to detect DNA cross-
linking in cells exposed to minimally cytotoxic doses of a 
variety of DNA cross-linking agents. By using this method, 
the kinetics of DNA interstrand cross-link formation and 
disappearance in the overall genome of the cells can be 
studied (Kohn et al., 1976). Theoretically, formation of DNA 
cross-links induced by a bifunctional agent requires a 
sequence of two steps: the reaction of the first functional 
group to form a monoadduct, followed by the reaction of the 
second functional group to form a cross-link. The time 
required by each agent to complete second step reaction 
varies. In the case of HN2, little or no lag in cross-linking 
10 
was detected in mammalian cells at 37°C (Ewig and Kohn, 1977; 
Ross et al., 1978), but for cisplatin there is a lag of 6 to 
12 h in the formation of interstrand cross-links (Zwelling et 
al. , 1978, 1979) . The levels of interstrand cross-links 
formed in tumor cells induced by either drug were inversely 
proportional to cell survival (Ewig and Kohn, 1977; Ross et 
al., 1978; Plooy et al., 1985; Zwelling et al., 1979 and 1981; 
Laurent et al., 1981; Erickson et al., 1981). A substantial 
amount of evidence indicates that DNA interstrand cross-links 
induced by either HN2 or cisplatin contribute significantly to 
the cytotoxicity (Colvin, 1982; Roberts and Thomson, 1979). 
However, since the cisplatin intrastrand adduct is the 
predominant lesion, many investigators believe this type of 
adduct also is the lethal lesion (Eastman, 1987). 
Overall, DNA damage generally is considered the predominant 
mechanism by which these two drugs exert their toxicity. 
However, some recent studies have indicated that other 
potential mechanisms exist (Epstein, 1990). One mechanism 
that has been implicated for several anti-tumor agents is 
inhibition of RNA transcription (Pieper et al., 1989). HN2-
or cisplatin-induced DNA lesions have been shown to block RNA 
polymerase transcription in vitro at selected guanine pairs in 
the HN2-treated DNA template, and at d(GG), d(AG), and d(GC) 
sites of cisplatin-treated DNA template (Pieper et al., 1989; 
Lemaire et al., 1991; Gray et al., 1991) • The cisplatin 
adducts at the d(GC) sites were identified as interstrand 
11 
cross-links. HN2 also has been shown to alter steady state 
mRNA levels of the c-myc oncogene, the expression of which is 
critical for cell proliferation (Futscher and Erickson, 1990). 
Further study of the effects of DNA cross-linking agents on 
gene expression in tumor cells may offer some insights to the 
factors contributing to anti-tumor activity induced by these 
agents. 
Heterogeneous DNA Damage and Repair 
DNA repair processes are cellular responses associated with 
the restoration of the normal nucleotide sequence of DNA after 
damage. The repair proficiency is usually assumed to be 
uniform throughout the genome. However, recent studies of DNA 
repair at the gene level have revealed that the DNA repair 
processes in the mammalian genome overall are heterogeneous 
(Bohr et al., 1987; Bohr, 1991) . This phenomenon was 
suggested in studies evaluating UV-survival characteristics in 
rodent and human fibroblasts (Ganesan et al., 1983). Twenty-
four hours after irradiation, the human cells removed 80% of 
the UV-induced pyrimidine dimers, while rodent cells removed 
less than 20% of these lesions. However, the rodent cells 
survived as well as human cells despite their low overall 
repair efficiency. This "repairadox" was explained by the 
possibility that rodent cells may selectively repair genes 
essential for cell survival. The finding that B-11 CHO cells 
remove UV-induced pyrimidine dimers from the dihydrofolate 
12 
reductase (DHFR) gene much more efficiently than from the 
overall genome supports this hypothesis (Bohr et al., 1985). 
In these cells, the expression of the DHFR gene is essential 
for survival, since the cells were maintained in methotrexate-
containing medium. Differential DNA repair also was noted 
when the repair rates of two proto-oncogenes (c-abl and c-mos) 
in swiss mouse 3T3 cells were compared. UV-induced dimers 
were removed faster in the transcriptionally active c-abl gene 
than in the transcriptionally inactive c-mos gene (Madhani et 
al., 1986). Furthermore, the transcribed strand of the DHFR 
gene was selectively repaired relative to the non-transcribed 
strand following UV irradiation (Mellon et al., 1987). 
In contrast to the homogeneous distribution of UV-induced 
pyrimidine dimers (Williams and Friedberg, 1979), extensive 
studies have revealed that DNA damage produced by many anti-
tumor agents exhibits a non-random pattern in the mammalian 
genome. For instance, nitrogen mustards react predominantly 
with guanines by alkylating their N-7 position in GC-rich 
regions to form DNA interstrand cross-links (Brooks and 
Lawley, 1961; Kohn et al., 1966, 1987 and 1988; Chun et al., 
1969; Mattes et al., 1986 and 1988; Hartley et al., 1988). 
Some DNA damaging agents appear to interact preferentially 
with transcribed genes or DNA associated with the nuclear 
matrix where transcription and replication are thought to 
occur (D'Andrea and Haseltine, 1978; Beckmann et al., 1987; 
Tulius and Lippard, 1981; Chiu et al., 1982; Ciejek et al., 
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l983; Irvin and Wogan, 1984; Gupta et al., 1985; Wassermann, 
1990; Futscher et al., 1992). These data link the 
accessibility of a gene to DNA damaging agents with the 
primary sequence and the functional state of the gene. 
However, the relative transcription activity of active genes 
has not been directly measured to determine whether or not the 
transcriptional state of a gene is related to its 
accessibility to DNA damaging agents. 
The production and disappearance of DNA interstrand cross-
links induced by DNA cross-linking agents can be assessed at 
the gene level by a novel assay developed by Vos and Hanawalt 
(1987). Using this technique, Futscher et al. (1992) 
demonstrated that HN2-induced DNA interstrand cross-links 
distribute in a heterogeneous fashion in human Colo320HSR 
cells. DNA interstrand cross-links are preferentially formed 
in the c-myc oncogene, which is amplified and overexpressed in 
this cell line. No DNA interstrand cross-links were detected 
in the lowly expressed N-ras oncogene, or the silent c-fos 
gene. These data are consistent with the notion that DNA 
damage in the mammalian genome overall is heterogeneous, and 
this heterogeneity may be coupled with the transcriptional 
activity of a gene. 
The relationship between the transcriptional state of a 
gene and its accessibility to HN2-induced DNA interstrand 
cross-links is studied in this dissertation. The relative 
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transcription rates and the production of DNA interstrand 
cross-links in different genes are compared. 
colo320HSR Cell Line 
The Colo320HSR cell line is used for this dissertation 
study, mainly because it contains an amplified and 
overexpressed c-myc oncogene and the characteristics of 
several other genes has been well documented in our laboratory 
(Futscher and Erickson, 1990; Futscher et al., 1992). Colo320 
cell line was isolated from the tumor of a 55-year-old 
Caucasian female patient with colon carcinoma before the 
initiation of chemotherapy (Quinn et al., 1979). Two sublines 
have been established due to their karyotype differences. 
Colo320HSR carries a chromosomal homogeneously staining 
chromosomal region (HSR), and Colo320DM has numerous double 
minute (DM). Colo320 cells (HSR or DM) possess amine precursor 
uptake and decarboxylation properties, such as ectopic 
production of norepinephrine, epinephrine, serotonin, 
adrenocorticotropic hormone, and parathyroid hormone. Colo320 
cells neither produce carcinoembryonic antigens, nor do they 
morphologically resemble other known carcinoma cell lines. 
These data suggest that Colo320 cells are of neuroendocrine 
origin rather than of colonic adenoepithelial origin (Quinn et 
al. , 1979) . 
By in situ hybridization analysis, the homogeneously 
staining region of the Colo320HSR marker chromosome was found 
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to contain a highly amplified c-myc oncogene. In addition, 
the amplification of c-myc has been accompanied by 
translocation of the gene from its normal position on 
chromosome 8 to a distorted X chromosome (8q24) (Alitalo et 
al., 1983). Colo320HSR cells have at least 15 to 20 copies of 
an apparently normal c-myc allele and 1 to 2 copies of an 
abnormal c-myc allele lacking exon 1. These cells express 
high levels of normal c-myc mRNA (Schwab et al., 1986). 
Although the tumorigenic etiology of Colo320HSR cells is 
not completely delineated, studies on oncogene expression have 
revealed that c-myc appears to be the only oncogene whose 
expression is enhanced in this cell line, suggesting that c-
myc amplification and overexpression may play a causal role in 
the development of colon carcinoma Colo320HSR (Alitalo et al., 
1983). The N-ras gene is expressed at a very low level, and 
the c-fos gene is silent in this cell line (Futscher and 
Erickson, 1990). 
The c-myc oncogene 
The c-myc gene belongs to a family of related genes that 
include N-myc and L-myc. There is a large body of information 
concerning oncogenic activation and the intricacies in the 
regulation of myc expression, as well as compelling evidence 
for the involvement of Myc protein in cell proliferation, 
mitogenesis, and differentiation. 
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A. The c-myc Gene Structure 
All normal c-myc transcription units are composed of three 
exons, the second two encoding the major c-myc proteins. 
Figure 2 provides summaries of a c-myc genomic DNA map, 
transcripts and open reading frames. A long untranslated exon 
1 is present in c-myc-related genes, however, these exons have 
little homology to each other (Kohl et al., 1986; Stanton et 
al., 1986; DePinho et al., 1987; Downs et al., 1989). These 
observations lend support to the notion that an important 
structural or regulatory role of the c-myc leader regions 
exists via a sequence-independent mechanism. The first exon 
has been postulated to be the site of translational (Parkin et 
al., 1988) and mRNA stability control (Pei and Calame, 1988). 
Near the end of exon 1, there is a site of transcriptional 
elongation blockage known to modulate c-myc expression in a 
number of cell types (Bentley and Groudine, 1986a, Bentley et 
al., 1989; Nepveu and Marcu, 1986; Eick and Bornkamm, 1986). 
Another conserved feature of the c-myc transcription unit 
is the presence of multiple transcription start sites. There 
are two major c-myc promoters, Pl and P2, located 161 bp apart 
in the human gene (Battey et al., 1983; Watt et al., 1983a). 
In normal cells, the P2 promoter predominates, giving rise to 
75-90% of steady state c-myc mRNA. Pl-initiated transcripts 
account for 10-25% of c-myc mRNA (Stewart et al., 1984; 
Bentley and Groudine, 1986a; Taub et al., 1984a and b; Spencer 
et al., 1990). Minor promoters lacking canonical RNA 
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polymerase II TATA sequences have also been identified. PO is 
located 550 to 650 bp upstream of Pl. P3 is positioned near 
the 3' end of intron 1 of the human gene. Transcripts 
initiated from these two promoters contribute less than 5% of 
steady-state c-myc RNA (Bentley and Groudine, 1986b; Ray and 
Robert-Lezenes, 1989). 
The sizes of the normal c-myc mRNA species are 
approximately 2.2 and 2.4 kb for major species initiating at 
the P2 and Pl promoters, respectively, and 3.1 and 2.3 kb for 
those minor transcripts initiating at PO and P3 promoters 
(Battey et al., 1983; Bentley and Groudine, 1986b; Ray and 
Robert-Lezenes, 1989). In some cell types, a 2.5 kb RNA has 
been detected that initiates near PO with a major portion of 
exon 1 removed by RNA processing (Bentley and Groudine, 
1986b). The half life of c-myc mRNA is about 10 to 30 minutes 
depending on the cell type (Dani et al., 1984). 
Antisense transcription in several regions of the human c-
myc gene has been detected by nuclear run-on transcription 
assays as depicted in Figure 2 (Bentley and Groudine, 1986a). 
There is, however, no evidence of stable antisense c-myc 
transcripts in human cells. The functional role of the 
antisense transcription is unknown. 
B. The c-Myc Protein 
There are two major c-Myc proteins, P64 and P67, derived 
from alternative initiation codons but sharing the same 
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reading frame in exons 2 and 3 (Hann et al., 1988). The ORF 
begins at an AUG codon at the 5' end of exon 2 and has been 
demonstrated to code for P64, a major in vivo c-myc protein 
(Hann and Eisenman, 1984; Ramsay et al, 1984). The second 
primary translation form, p67, is translated from an open 
reading frame beginning at a CUG initiation codon at the 3 1 
end of exon 1 and thus contains an additional 15 amino acids 
at amino terminus (Hann et al., 1988). 
c-Myc proteins are short-lived nuclear phospho-proteins 
modified by phosphorylation on serine and threonine residues 
in a region spanning the exon 2/exon 3 boundary. Despite 
close to 3000 publications relating to the Myc family genes, 
there is no strong consensus as to their molecular function. 
over the last few years, two competing models for Myc function 
have emerged and have received varying degrees of experimental 
support. These include a role in DNA replication and 
regulation of gene expression at transcriptional and post-
transcriptional levels (for review, see Luscher and Eisenman, 
1990) . 
The structure of c-Myc protein has several significant 
features. The carboxyl terminus of Myc family proteins 
contains a basic region and a helix-loop-helix leucine zipper 
motif (BR-H-L-H-Zip) (for review, see Luscher and Eisenman, 
1990). The leucine zipper is a 20- to 30-residue-long 
amphipathic a-helix with a leucine residue situated at every 
second helical turn (i.e., every 7 residues) (Landschulz et 
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al., 1988). The function of the zipper as a protein-protein 
interaction domain appears in many cases to be closely coupled 
to a DNA-binding activity. In c-Myc, N-Myc, and L-Myc, the 
region of helix-loop-helix motif (H-L-H) also preceded by a 
basic region covers a block of ~55 amino acids located ~30 
residues before their carboxyl termini. The remaining 30 
carboxy-terminal amino acids possess the leucine zipper motif. 
These two features are common structure motifs found in 
transcriptional regulators (Jones, 1990; Olson, 1990). Many 
studies indicate that the homology region has a functionally 
bipartite structure with the H-L-H segment involved in homo-
and heterotypic protein-protein interactions, while the basic 
regions are involved with DNA binding (Lassar et al., 1989; 
Murre et al., 1989a and b; Davis et al., 1990). The 
inability to demonstrate specific DNA binding, or to find 
conclusive evidence for the ability of Myc to form homotypic 
and/or heterotypic complexes with known transcription factors, 
argues against the possibility that c-Myc may function as a 
transcription regulator. However, the discovery of Max, a 
myc-associated-protein, which also possesses a BR-H-L-H-Zip 
domain and binds to c-Myc in a manner that depends on the 
integrity of the c-Myc carboxyl terminus, may shed some light 
on Myc function (Blackwood and Eisenman, 1991). 
The strong correlation between cell proliferation and 
expression of c-Myc has made the possibility of the 
involvement of Myc in DNA replication rather attractive. 
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Antisense oligonucleotides to c-myc resulted in a cessation of 
proliferation, and inhibited the entry of cells into the s 
phase (Heikkila et al., 1987; Holt et al., 1988) . In 
addition, some studies have shown that c-Myc protein can bind 
and promote DNA replication at replication origins of both 
SV40 and c-myc itself (Luscher and Eisenman, 1990). Overall, 
experimental results are consistent with the notion that c-Myc 
might be involved in replication, but it remains unclear as to 
the mechanism by which Myc acts. 
c. Regulation of c-myc Expression 
studies on the regulation of c-myc gene expression revealed 
a complex array of mechanisms, including both transcriptional 
and post-transcriptional regulation. Steady state c-myc mRNA 
levels have been correlated with the cellular growth state. 
In general, levels of c-myc RNA are 10 to 40-fold higher in 
growing cells than in quiescent cells (Kelly et al., 1983; 
Dean et al., 1986). Initially, it had also been suggested 
that c-myc RNA levels might be regulated during the cell 
cycle, but it was subsequently shown that both RNA and protein 
levels are constant in cycling cells (Hann et al. , 1985; 
Thompson et al., 1985). In contrast to the constant c-myc RNA 
levels in proliferating cells, decreased c-myc RNA levels are 
associated with some cells exiting the cell cycle, or 
undergoing terminal differentiation (Bentley and Groudine, 
1986a; Simpson et al., 1987; Siebenlist et al., 1988). 
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control of c-myc transcription initiation is mediated 
through a composite of positive and negative cis-acting 
transcription initiation elements (for review, see Spencer and 
Groudine, 1991). In vivo, steady state c-myc RNA is 
synthesized from PO, Pl, P2, and P3 promoters by RNA 
polymerase II (Spencer and Groudine, 1990). Control over the 
elongation phase of transcription in the c-myc gene provided 
the first example of a eukaryotic gene regulated 
transcriptionally by an attenuation mechanism (Bentley and 
Groudine, 1986a; Eick and Bornkamm, 1986). Nuclear run-on 
analysis revealed a molar excess of exon 1 relative to exon 2 
transcription in HL60, Hela, and Colo 320 cells, indicating 
the existence of a block to transcription elongation near the 
3 1 end of exon 1 (Bentley and Groudine, 1986a). Furthermore, 
modulation in the half-life of c-myc mRNA and protein provides 
a commonly observed mechanism of c-myc regulation (reviewed in 
Piechaczyk et al., 1987). 
D. Oncogenic Activation of the c-myc Gene 
The c-myc proto-oncogene is activated by several different 
mechanisms that result in the unrestrained growth of tumor 
cells. The mechanisms of activation include proviral 
insertion, chromosomal translocation, and gene amplification 
(Varmus, 1984; Rabbits, 1985; Cole, 1986; Alitalo et al., 
1987). The first demonstration that cellular proto-oncogenes 
could be activated in tumor cells was the finding that avian 
23 
1eukosis virus was integrated into the c-myc locus in viral-
induced B-cell lymphomas (Hayward et al., 1981). Consistent 
chromosomal translocations in c-myc are characteristic of 
murine plasmacytomas (Adams et al. , 1983; Crews et al. , 1982) , 
human Burkitt's lymphomas (Taub et al., 1982; Dalla-Favera et 
al. , 1983) and human T cell tumors (Hollis et al. , 1988; 
Finver et al., 1988). Amplification of c-myc occurs in a 
number of human tumors, such as promyelocytic leukemia 
(Collins and Groudine, 1982; Dalla-Favera et al., 1982), some 
small-cell lung carcinomas (Little et al., 1983; Krystal et 
al. , 1988) , breast sarcomas (Escot et al. , 1986) , colon 
carcinoma (Alitalo et al., 1983), and osteosarcomas (Bogenmann 
et al., 1987). Each of these mechanisms involves DNA 
rearrangements that lead to constitutive or elevated levels of 
c-myc expression. Thus, c-myc promotes tumor-cell growth via 
quantitative increases in c-Myc protein level, rather than by 
qualitative changes in the c-Myc protein. On the other 
hand, a consistent feature of tumors containing an activated 
c-myc gene is that the level of c-myc RNA is invariably higher 
(10 to 50 fold) than the low level found in quiescent cells 
(Keath et al. , 1984) . These observations have led to a 
consensus that it is deregulation of c-myc expression, or an 
inability to turn the gene off, that is essential for 
activation. 
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GAPDH Gene 
Glyceraldehyde-3-phosphate dehydrogenase (EC 1.2.2.12)is 
a key enzyme in the control of glycolysis, 
conversion of glyceraldehyde-3-phosphate 
catalyzing the 
to 1, 3-
diphosphoglycerate (Dandliker and Fox, 1955; Fox and 
oandliker, 1956; Harris and Perham, 1963). The GAPDH protein 
is a tetramer composed of identical subunits of 37,000 
molecular weight (Fox and Dandliker, 1956; Harris and Perham, 
1963) . 
GAPDH belongs to a large multiple gene family. This gene 
family contains 150 or more GAPDH-like sequences, many of 
which are processed pseudogenes (Piechaczyk et al., 1984a; Tso 
et al., 1985). Only one gene coding for GAPDH is known to be 
functional in human, mouse, rat and chicken (Herbschleb-Voogt 
et al., 1978; Bruns et al., 1978 and 1979; Serville et al., 
1978; Alevy et al., 1984). This gene has been localized to 
chromosome 12 in humans (Bruns et al., 1978; Serville et al., 
1978). The protein sequence of GAPDH is highly conserved among 
six different organisms studied to date (Dayhoff, 1978) . 
Comparison of GAPDH sequences between human, rat and chicken 
revealed a high degree of conservation at both the cDNA and 
protein levels (Tso et al., 1985; Fort et al., 1985). 
The functional human GAPDH gene was isolated and 
characterized by Ercolani et al. ( 1988) . The gene consists of 
9 exons and 8 introns with eukaryotic signals necessary for 
the transcription and translation of GAPDH mRNA. Stable 
25 
transfection of rodent cells with the intact human GAPDH gene 
resulted in the expression of a correctly initiated human 
GAPDH mRNA and an enzymatically active human GAPDH 
polypeptide, indicating that the gene contains a functional 
promoter and intact coding sequences. Although many GAPDH 
pseudogenes and GAPDH-like sequences are present in the human 
genome, the single copy functional GAPDH gene can be 
identified on a Southern blot by using an intron segment of 
the gene (Ercolani et al., 1988). 
c-fos oncogene 
The human c-fos proto-oncogene was found as the cellular 
homolog of oncogenes carried by two murine retroviruses, FBR 
and FBJ osteogenic sarcoma viruses (Van Beveren et al., 1983; 
Van Straaten et al., 1983). The c-fos gene maps to the 
chromosome region 14q21-q31 (Barker et al., 1984). It was 
cloned as a 9.0 kb genomic DNA fragment from a human 
lymphoblast cell line and has four exons which cover about 3.4 
kb (Curran et al., 1983). The polyadenylated c-fos mRNA is 
approximately 2.2 kb in size and encodes a 380 amino acids 
long protein (Curran, 1988). 
The c-fos proto-oncogene is expressed at low or 
exponentially growing cells, undetectable 
although it 
levels in most 
can 
numerous stimuli. 
be activated transiently in response to 
The best characterized experimental system 
is quiescent fibroblasts which are induced to grow upon the 
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addition of growth factors. c-Fos protein accumulates 
quantitatively and rapidly in the nucleus, peaks at 1-2 h 
after stimulation, and disappears totally within 3-8 h, the 
length of each phase being cell type dependent (Kruijer et 
al., 1984; Muller et al., 1984; Vosatka et al., 1989). 
Normal c-Fos protein is oncogenic both in vitro (Miller et 
al., 1984) and in vivo (Ruther et al., 1989) when expressed at 
an inappropriate level. To date, no rearrangements in the c-
fos gene have been identified in DNA from human tumors 
(Curran, 1988) . 
Regulation of c-fos gene expression is complex and involves 
both transcriptional and post-transcriptional mechanisms. At 
the level of transcription initiation, several cis-acting 
elements of the gene bind trans-acting factors, which are 
responsible for the basal expression of the promoter 
(Treisman, 1985 and 1986; Gilman et al., 1986; Greenberg et 
al., 1987), or the induction by various agents such as serum 
(Treisman, 1985 and 1986), phorbol esters (Hayes et al., 1987; 
Gilman, 1988; Sheng et al., 1988; Siegfried and Ziff, 1989), 
cAMP (Sassone-Corsi et al., 1988; Fisch et al., 1989), and DNA 
damaging agents (Hollander and Fornace, 1989; Futscher and 
Erickson, 1990). At the post-transcriptional level, c-fos 
mRNA is highly unstable, thus providing a rapid shut-off of 
gene activity. Several defined regions appear to contribute 
to the rapid degradation of the mRNA, the use of each 
depending on the physiological conditions (Shyu et al., 1989). 
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The c-Fos protein is a short-lived nuclear phosphoprotein. It 
is capable of stimulating gene expression not by direct 
binding to DNA but by interaction with transcriptional factors 
such as the members of the Jun family in the AP-1 complex 
(Chiu et al., 1988; Franza et al., 1988; Halazonetis et al., 
1988) . 
Histone H3.3 Gene 
Histones are a class of basic proteins that are complexed 
with DNA to form the eukaryotic chromosome. Hi stone genes are 
transcribed into non-polyadenylated mRNAs, and no intron is 
found in most of the genes in histone family. In vertebrates, 
the regulation of histone genes is typically cell-cycle-
dependent, with the expression being linked to ongoing DNA 
replication (Reviewed in Maxson et al., 1983). 
In contrast to the classic histone genes, the H3.3 histone 
gene is expressed in a replication-independent manner (Wu and 
Bonner, 1981; Wu et al., 1983). The gene contains 3 introns 
and spans greater than 8 kb of genomic DNA. The processed 
histone mRNA is about 1.2 kb long, and contains unusually long 
5' and 3 1 untranslated regions, and has a 3 1 polyadenylated 
tail (Wells and Kedes, 1985; Wells et al. , 1987) . This 
variant basal histone somehow escapes the cell-cycle 
regulation and its protein function is unknown. 
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s-actin gene 
cytoplasmic actins (B-actin and r-actin) constitute the 
major component of the microfilamentous structures and 
participate in a variety of cell functions. B-actin is one of 
the most abundant cellular proteins in mammalian non-muscle 
cells (for review, see Clarke and Spudich, 1977). 
The B-actin gene contains six exons and five intrans 
(Gunning et al., 1983; Nakajima-Iijima et al., 1985). The 
nucleotide sequences of the B-actin exons are highly conserved 
among human, rat and chicken. The amino acid sequence deduced 
from the human B-actin gene is exactly the same as that of the 
chicken B-actin gene and differs by only one amino acid from 
that of rat B-actin gene (Nakajima-Iijima et al., 1985). 
The expression of B-actin gene is controlled by several 
sequences resided in the 5 1 flanking and first intron regions, 
such as a TATA box, a CCAAT box, and a serum response element 
(Sugiyama et al., 1988; Frederickson et al., 1989; Orita et 
al., 1989). However, the regulation of expression of the B-
actin gene is a complicated process which requires further 
elucidation. 
MATERIALS AND METHODS 
cell culture 
The cell line Colo320HSR was purchased from the American 
Type Culture Collection. Cells were maintained in suspension 
at 37•c in an atmosphere of 95% air/5% CO2 in RPMI 1630 medium 
(Irvine Scientific, CA) containing 15% heat-inactivated bovine 
calf serum (HyClone Laboratories, Logan, UT), 2 mM L-
glutamine, 50 units penicillin, and 50 µg/ml streptomycin (JRH 
Biosciences, Lenexa, KS) . Cells were passed once a week 
before they reached the density of 1 X 106 cells/ml. Cell 
number was determined by counting on a Coulter Counter Model 
ZBI (Coulter Electronics, Inc., Hialeah, FL). 
To obtain a serum-starved population of Colo320HSR, cells 
were seeded at 1 X 105 cells/ml and grown to their maximal 
density of 1.0 to 1.2 X 10 6 cells/ml over a period of 4-5 days 
in complete medium, and kept in stationary phase for three 
days without changing medium. These serum-starved cells were 
pelleted, and incubated in either fresh warm medium, or the 
same medium in which the cells were grown (conditioned medium) 
at a density of 5 X 105 cells/ml for 3 h before drug 
treatment. 
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Reagent Preparation 
r. DNA Cross-linking Agents 
HN2 and cisplatin were obtained from the Drug Development 
Branch, National Cancer Institute. HN2 was prepared as a 10 
mM solution in sterile filtered 0.1 N HCl and stored at -20°c. 
cisplatin was dissolved in complete conditioned medium (RPMI 
1630 plus 15% calf serum) as a 500 µM solution by stirring at 
37°c for 30 min just before use. Conditioned medium was 
defined as the same medium the cells were grown in before drug 
treatment. 
II. General Chemical Agents 
Glyoxal was obtained as powder and dissolved in DEPC-
treated (diethyl pyrocarbonate) water as a 7 M stock solution 
(Sigma Chemical Co., St. Louis, MO). To facilitate the 
melting of glyoxal, the solution was heated to 55°C for 30 
min. Glyoxal stock solutions were deionized by mixing with 
resin RG 501-XS (Bio-Rad Laboratories, Richmond, CA) at room 
temperature until the pH of the solution was greater than 5.0. 
Small aliquots were stored at -80°C in tightly capped 
microfuge tubes. 
discarded. 
Each aliquot was used only once and 
Formamide was purchased from BRL as a 100% solution. 
Formamide was deionized twice by stirring with RG 501-XS resin 
(5 g/100 ml) at room temperature for 30 min. The solution was 
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filtered through 3 MM Whatman paper and stored at -2o·c in 
aliquots. 
Phenol was purchased as a frozen stock (BRL, Gaithers-burg, 
MD). Following melting at 68°C in a water bath, 
hydroxyquinoline was added to phenol with a final 
concentration of 0.1%. Hydroxyquinoline protects phenol from 
oxidization and adds a slight yellow color to the colorless 
phenol. Phenol was equilibrated to a pH >7.8 by mixing with 
an equal volume of 1 M Tris-HCl (pH 8.0) several times, and 
finally with 0.1 M Tris-HCl (pH 8.0). The phenol solution was 
stored at 4°C for up to a month. 
All chemical solutions used for RNA preparation were either 
treated with DEPC or dissolved in DEPC-treated water. DEPC 
treatment was carried out by adding 100% DEPC to a final 
concentration of 0.1-0.2%, stirring at room temperature for at 
least 12 h, and autoclaved for 40 min at 15 lb/sq. in. 
pressure using liquid cycle. 
Drug Treatment 
To study effects of DNA cross-linking agents on gene 
expression, exponentially growing cells were seeded into 
individual flasks at a density of 2.5 X 10 5/ml and grown at 
37°C overnight. 24 h after seeding, cells were exposed to 
various concentrations of either drug or vehicle (0.1 N HCl 
for HN2, or conditioned medium for cisplatin) for 1 hat 37°C. 
The drug was removed by washing the cells twice with warm 
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medium. Finally, the cells were incubated in warm fresh 
complete medium (RPMI 1630 plus 15% heat-inactivated bovine 
calf serum) for o, 6, 12, 24, or 36 h. After incubation, 
cells were collected and analyzed. In addition, mock samples 
were set up for the corresponding time point control to 
monitor normal fluctuations of c-myc expression. 
For studies on the accessibility of various genes to HN2-
induced DNA interstrand cross-links, exponentially growing 
cells were set up at the same density as controls for serum-
starved samples. Cells were exposed to 6. 25 µ.M HN2, or 
vehicle for 1 hat 37°C. Then cells were washed twice with 
ice-cold 1 X PBS to remove the drug and harvested immediately 
for DNA, RNA and nuclei isolation. 
Colony Formation Assays 
Cytotoxicity induced by either HN2 or cisplatin was 
determined by soft agar colony formation assays as described 
by Chu and Fisher (1968). After drug treatment, resuspended 
cells were counted and 102 to 105 cells were seeded in 
triplicate into sterile tubes (Falcon 2054, 12 X 75 mm style, 
Becton Dickinson and Company, Lincoln Park, NJ) containing 
noble agar with a final concentration of 0.1% (DIFC 
Laboratories, Detroit, MI). Cells were grown for 14 days to 
produce clones of appropriate size for visual counting. The 
surviving fraction was calculated in relation to the control 
(cells without drug exposure). 
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g_eneral Methods 
r. Nucleic Acids Isolation 
A. Plasmid DNA Isolation 
i). Large Scale Preparation of Plasmid DNA 
To obtain large quantities of plasmid DNA for hybridization 
studies, equilibrium centrifugation in cesium chloride-
ethidium bromide gradients was used. Bacteria carrying the 
plasmid of interest were grown overnight in 1 L Luria-Bertani 
medium (LB broth) (10 g Bacto-tryptone, 5 g Bacto-yeast 
extract, and 10 g NaCl) with the appropriate antibiotic in a 
2-L flask at 37°C, shaken vigorously (225 rpm) in a bacterial 
orbital incubator-shaker until the OD600 of the resulting 
culture was between O • 4 to O. 6 . For cultured bacteria 
harboring low-copy-number plasmids, amplification of plasmids 
was carried out by adding chloramphenicol (Sigma, St. Louis, 
MO) to the culture (final concentration of 170 µg/ml) and 
incubating the culture for an additional 12-16 h. 
The bacteria were lysed by the SDS (sodium dodecyl sulfate) 
protocol (Sambrook et al., 1982) . Bacterial cultures ( 500 mls) 
were pelleted at 3750 rpm (4000 X g) in the Beckman Model J-6M 
centrifuge at 4°C for 10 min. The pellet was washed once with 
lX PBS, and resuspended in 10 ml of ice cold 10% sucrose, 50 
mM Tris, pH 8.0. This 10 ml solution was split into 4 thick-
walled polycarbonate tubes. To each tube, O. 5 ml lysozyme ( 10 
mg/ml, dissolved in 0.25 M Tris, pH 8.0) and 2 ml of 0.25 M 
EDTA were added, the tubes were gently inverted and then 
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incubated on ice for 10 min. One ml of 10% SDS, and 1.5 ml of 
5 M NaCl were added sequentially to each tube, then the tubes 
were gently inverted for 20 times. The lysate was incubated 
on ice for 1 h. The bacterial debris was removed by 
ultracentrifugation (Beckman Model L8-70M) in a Beckman Ti70.1 
fixed angle rotor at 30,000 rpm (83,000 X g) at 4°C for 30 
min. The aqueous layer was extracted twice with an equal 
volume of phenol/chloroform/isoamyl alcohol (25:24:1), and 
once with chloroform/isoamyl alcohol (24:1) to remove protein. 
Phases were separated by centrifuging the mixture in the 
Beckman Model J-6M at 2370 rpm (1600 X g) at 22°c for 10 min. 
Nucleic acids were precipitated by the addition of 2. 5 volumes 
of ice-cold 95% ethanol (Kodak, New Haven, CT). Nucleic acids 
were recovered by centrifugation in a Sorvall RC-5B centrifuge 
(DuPont) using the ss-34 rotor at 4°C for 30 min at 10,000 rpm 
(10,000 X g) . Nucleic acids were dried under vacuum, 
resuspended in TE, pH 8.0 and treated with RNAse (10 µg/ml) 
for 1 hat 37°C. This solution was extracted with organic 
solvents again to remove proteins. Supercoiled plasmid DNA 
was separated from the linear bacterial chromosomal DNA by 
equilibrium centrifugation in cesium chloride-ethidium bromide 
gradients. DNA was centrifuged in 6 M CsCl (BRL, Gaither-
sburg, MD), 0.8 mg/ml ethidium bromide gradients in Beckman 
Ti70.1 ultracentrifuge (45,000 rpm) for 48 hat 20°c. After 
centrifugation, the supercoiled plasmid DNA band was collected 
using a 18 g syringe needle. Ethidium bromide was removed by 
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extracting plasmid DNA with isoamyl alcohol 5 times. The 
plasmid DNA was dialyzed against TE (10 mM Tris-HCl, pH 8.0, 
and 1 mM EDTA), pH 8.0, and concentrated by ethanol 
precipitation. The identity of plasmid was always confirmed 
by its restriction enzyme digestion pattern before and after 
a large scale preparation. 
ii). Small Scale Preparation of Plasmid DNA 
To isolate small amounts of plasmid DNA from different 
bacterial clones, the alkaline lysis miniprep method was 
employed (Ausubel et al., 1989). Bacteria were grown in 5 ml 
LB overnight at 37 •c, shaken vigorously in a Roto-torque 
shaker (Cole-Parmer Instrument Company, Chicago, IL). The 
bacteria were pelleted in a microcentrifuge tube, and 
resuspended completely in 100 µl TE, pH 8.0. The bacteria 
were lysed by adding 200 µl solution containing 1% SDS and 0.2 
N NaOH, and incubating on ice for 5 min. The mixture was 
neutralized with 150 µl 3M potassium acetate, which cause the 
plasmid DNA to reanneal rapidly. The bacterial debris and 
chromosomal DNA were pelleted by spinning the sample in a 
Beckman Model E centrifuge for 5 sec at 12, ooo rpm. The 
supernatant was saved and mixed with 0.9 ml of 100% ethanol at 
room temperature to precipitate nucleic acids. The nucleic 
acids were pelleted by centrifugation for 20 sec in Beckman 
Model E centrifuge. The pellet was washed with 70% ethanol 
and dried under vacuum. The pellet was resuspended in 20 µl 
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TE, pH 8. 0 and RNAse ( 10 µg/ml) buffer and subjected to 
further analysis. 
B. Total Cellular RNA Isolation 
Total cellular RNA was isolated basically by following the 
guanidinium isothiocyanate method (Chirgwin et al., 1979). 
cells were washed free of media in 1 X ice cold PBS by 
centrifuging at 1800 rpm (800 X g) for 5 min twice in a 
Beckman Model TJ-6 table top centrifuge. The cell pellet was 
lysed by the addition of 3. 5 ml guanidinium solution ( 4 M 
guanidinium isothiocyanate, 0. 02 M sodium acetate, 0. 01 M 
dithiothreitol (DTT), 0.5% Sarkosyl solution). The 
chromosomal DNA was sheared by passing the cell lysate through 
a 20 gauge syringe needle 4 times. The lysate was either 
stored at -85°C or centrifuged immediately. To isolate RNA, 
the 3.5 ml cell lysate was carefully layered onto a 1.5 ml of 
5. 7 CsCl, 0. 1 mM EDTA cushion in an ultra clear 
ultracentrifuge tube (Beckman, 14 X 95 mm), and centrifuged at 
35,000 rpm in a Beckman Model L8-70M using a SW-40Ti rotor at 
l8°C for at least 16 h. The supernatant was decanted and the 
RNA pellet was drained for 5 to 10 min. The RNA pellet was 
resuspended in 360 µl DEPC-treated H2O, transferred to a clean 
1. 5 ml microfuge tube, and precipitated with ethanol. The RNA 
was pelleted in a Beckman Microfuge 11 by spinning at 12,000 
X g at 4°C for 30 min. The RNA was finally reconstituted in 
the appropriate amount of water to reach a concentration of 
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approximately 5 µg/µl and stored at -80°C for further 
analysis. 
c. Genomic DNA Isolation 
Genomic DNA was isolated from cells following a protocol 
described previously (Futscher et al. , 1992) . Cells were 
pelleted and washed free of media with 1 X ice cold PBS, pH 
7. 4. The cell pellet was dispersed by gentle vortexing. 
cells were then lysed by adding lysis buffer (0.05 M 
NaHCO3/Na2CO3 , 1 mM EDTA, 0. 5% N-Lauryl Sarcosine (w/v) , and 
o. 3 mg/ml proteinase K, pH 10. 4) to 3 X 106/ml ( 10 to 15 X 
106/ml total). The cell lysate was incubated at 37°C for at 
least 3 to 4 h with periodic mixing to ensure complete 
digestion of protein. 
The cell lysate was deproteinized by extracting with equal 
volume of phenol/chloroform/isoamyl alcohol (25:24:1) twice, 
and chloroform/isoamyl alcohol (24:1) once. The cell lysate 
and organic solvents were mixed until an emulsion was formed. 
After separation of the aqueous and organic phases by 
centrifugation in a Beckman J-6M centrifuge at 2370 rpm (1600 
X g) at 22°c for 10 min, the genomic DNA was recovered from 
the aqueous phase by transferring to an Erlenmeyer flask. 0.2 
volume of 11 M ammonium acetate and 2.5 volumes of ice cold 
95% ethanol were added to precipitate the DNA. The DNA 
precipitate was spooled on to a glass rod, washed several 
times by dipping into 70% ethanol, and dissolved in 400 µl 
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820. The DNA solution was treated with RNase A (Sigma, st. 
Louis, MO) at a final concentration of 0.1 µg/ml at 37°C for 
3o min. Following RNase digestion, the DNA solution was 
deproteinized again by extraction with phenol/chloroform-
/isoamyl alcohol once, and chloroform/isoamyl alcohol once. 
The extraction and phase separation were carried out in a 
microfuge tube and centrifuged in a fixed angled rotor in 
Beckman Microfuge 11 at 500 X g for 5 min. The DNA was 
precipitated by adding 0.1 volume of 3M sodium acetate and 
2.5 volumes of ice cold 95% ethanol. The DNA precipitate was 
washed and resuspended in 400 µl TE, pH 8, at 4°C overnight. 
The DNA solution was ready for quantitation and restriction 
enzyme digestion. 
II. Nucleic Acid Quantitation 
Two methods were frequently used to estimate the amount of 
nucleic acid in a solution. To accurately quantitate RNA or 
DNA concentrations, a spectrophotometric determination method 
was used. The concentration of nucleic acid was also 
estimated by a minigel method when the amount of nucleic acid 
was minuscule. 
A. Spectrophotometric Quantitation of DNA or RNA 
A small aliquot of the DNA or RNA sample was quantitated by 
UV spectrophotometry. The readings at wavelengths of 260 nm 
and 280 nm were taken. An OD reading of 1.0 corresponds to 
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approximately 50 µg/ml of double-stranded DNA, or 40 µg/ml 
single-stranded RNA. The purity of DNA and RNA preparations 
was estimated by the ratio of the readings at 260 and 280 nm 
(OD260/OD280 ) • Pure preparations of DNA and RNA have OD260/OD280 
ratios of 1. 8 and 2 . o, respectively. Total cellular RNA and 
genomic DNA used for northern and Southern blot analysis were 
quantitated by this method. 
B. Minigel Method 
This method was used to estimate small amounts of DNA in 
solution. An aliquot of DNA sample was electrophoresed along 
with a serial dilution of DNA solutions with known 
concentrations through a 0.8% agarose minigel containing 
ethidium bromide ( O. 5 µg/ml) . The intensity of fluorescence of 
the unknown DNA was compared with that of the DNA standard, 
thus allowing a rough estimation of the quantity of DNA in the 
sample. This method was frequently used to check DNA 
quantitation in subcloning of DNA fragments. 
III. Purification and Concentration of DNA 
DNA fragments eluted from agarose gels or generated from 
PCR reactions were usually contaminated with agarose gel 
particles and organic solvents. Purification and 
concentration were required before further applications. 
Elutip minicolumns containing a matrix similar to RPC-5 resin 
were used to absorb up to 100 µg of nucleic acids (size from 
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50 bp to 50,000 bp) (Schleicher & Schuell, Inc., Keene, NH). 
The minicolumn was first wetted with low salt buffer (0.2 M 
NaCl, 20 mM Tris-HCl, pH 7.4, 1.0 mM EDTA). A DNA sample 
suspended in the low salt solution was applied to the column 
with a standard Luer-lock syringe. After washing the column 
with the low salt buffer, the DNA was eluted by high salt 
buffer (1 M NaCl, 20 mM Tris-HCl, pH 7.4, 1 mM EDTA) in 1 ml 
or less. 
IV. Agarose Gel Electrophoresis 
A. DNA Agarose Gel Electrophoresis 
DNAs from 100 bp to approximately 50 kb in length can be 
separated on agarose gels of various concentrations (0. 5-1. 4%, 
w/v). SeaKem GTG Agarose (FMC, Rockland, ME) was melted in 
0.5 X TBE buffer (45 mM Tris-HCl, 45 mM Boric acid, 1 mM EDTA, 
pH 8.0) by heating in a microwave oven, and cooled to 55°C. 
Ethidium bromide was added to a final concentration of 0.5 
µg/ml and mixed thoroughly before casting agarose solution in 
an appropriate size gel apparatus (BRL "Babygel" BRL 
Horizon 58, or FMC "Resolute"). The gel was allowed to set 
completely at room temperature, and depending on the agarose 
concentration, complete solidification occurred in 30 to 60 
min. The solidified gel was submerged in 0.5 X TBE buffer (45 
mM Tris-borate, 1 mM EDTA) until electrophoresis. 
DNA samples were mixed with 6 X loading buffer (0.25% 
bromophenol blue, 40% sucrose in water) unless otherwise 
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noted, and loaded into the wells of the submerged gel. One or 
more marker DNAs of known size were also included in each gel, 
such as 123 bp ladder, 1 kb ladder, or the supercoiled DNA 
ladder (BRL, Gaithersburg, MD). The gel was electrophoresed at 
1-5 volts/cm (measured as the distance between the 
electrodes). DNA banding was examined by UV light and the 
photograph taken by using a Fotodyne UV-440/Polaroid MP-4 
photographic transilluminator system (Fotodyne Inc., New 
Berlin, WI). 
B. RNA Agarose Gel Electrophoresis 
Agarose gels were prepared in the same way as the gels used 
for DNA electrophoresis except that agarose was dissolved in 
RNA running buffer ( 10 mM Na2HPO4/NaH2PO4 I pH 6. 8) . Usually 1% 
agarose gels were used to separate total cellular RNA. 
RNA samples were denatured in 50% dimethyl sulfoxide (DMSO) 
(Sigma, St. Louis, MO), 1 M glyoxal, 0.01 M Na2HPO4/NaH2PO4, pH 
6.8, at 50°C for 1 h. The denatured RNA samples were chilled 
on ice and centrifuged for 3 sec to deposit all of the fluid 
in the bottom of the microfuge tube. The RNA samples were 
mixed with 1/6 volume of loading dye (6 X, 40% sucrose, 0.25% 
bromphenol blue), and immediately loaded into the preformed 
wells. The gel was run at 100 volts for 20 min to allow RNA 
samples to enter the gel. Then a ministalic pump (Manostat 
Corp., New York, NY) was turned on to circulate the running 
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buffer in order to maintain the pH at less than 8. The time 
needed to separate total cellular RNA was about 3 h. 
To size an unknown RNA transcript, either a 0.24-9.5 kb RNA 
ladder (BRL) was added into outside lanes or 28 and 18 S rRNAs 
in total RNA were used as markers. RNA markers were cut from 
the gel and stained with ethidium bromide after 
completion of gel electrophoresis. 
v. Nucleic Acid Blotting 
After completion of agarose gel electrophoresis, nucleic 
acids were transferred to a GeneScreen Plus nylon membrane 
(DuPont, Boston, MA) by a capillary blotting procedure 
basically as described by Southern (1975). 
To transfer DNA, the gel was immersed in the following 
solutions sequentially before blotting: 0.25 N HCl for 15 min; 
0.5 M NaOH, 0.4 M NaCl for 30 min, and 0.5 M Tris-HCl, pH 7.5 
and 3 M NaCl for 45 min. The acid treatment allows 
depurination of DNA to occur. The depurinated sites are 
cleaved during the alkali treatment and the smaller DNA 
fragments transfer more efficiently. The bromphenol blue 
tracking dye should change from blue to yellow when the acid 
treatment is complete. The dye should return to blue when the 
basic denaturation step is complete. 
The gel was carefully placed on a wick ( two pieces of 3 MM 
Whatman paper) whose ends were soaked in 10 X SSC buffer (1 X 
SSC is 0.15 M NaCl, 15 mM trisodium citrate, pH 7.0). A 
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Genescreen Plus membrane, which was cut into the same size as 
the gel and presoaked in 10 X SSC for 15 min, was carefully 
placed on top of the gel. Air bubbles were then eliminated by 
cautiously rolling a 5 ml-pipette on the gel. Three pieces of 
3 MM Whatman paper, a stack of absorbent towels, and a weight 
of approximately 500 g were sequentially placed on top of the 
membrane. The transfer was allowed for at least 18 hours. 
The absorbent pads were changed whenever necessary. The 
weight, pads, and 3 MM filter papers were removed by the end 
of the transfer. The membrane was treated with 0.4 N NaOH for 
45 sec, then neutralized in 0.2 M Tris-HCl, pH 7.5, 2 X SSC 
for one min. The filter was air-dried before hybridization. 
The RNA blotting procedure was the same as the DNA 
transfer with two minor modifications. First, gels were not 
subjected to the depurination, denaturation, and 
neutralization steps as in DNA transfer. Second, after the 
transfer, the membrane was treated with 50 mM NaOH for 15 sec 
to reverse the glyoxal reaction and neutralized in 0.2 M Tris-
HCl, pH 7.5, lX SSC for 35 sec before air-drying. 
VI. Filter Hybridization 
The membrane was prehybridized in a solution containing 50% 
formamide, 10% dextran sulfate, 5 X SSPE (1 X SSPE is 0.15 M 
NaCl, 10 mM dibasic sodium phosphate, 1 mM EDTA, pH 7.4), 1% 
sos, 1 X Denhardt's (0.02% Ficoll 400, 0.02% polyvinyl 
pyrrolidone, 0.02% bovine serum albumin Pentax Fraction V), 
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and 250 µg denatured salmon sperm DNA in a plastic bag for at 
least 4 hat 42°C in a shaking waterbath. Hybridization was 
carried out in the same solution, at 42°C for a minimum of 24 
h with a 32P labeled probe (10 6 cpm/ml). The probe was 
denatured by boiling for 5 min and chilled on ice before 
adding into the hybridization bag. The probe was mixed well 
with hybridization solution before incubation at 42°C. After 
hybridization, the blot was washed in 250 ml of 2 X SSPE, 0.5% 
sos at room temperature, then washed at 65°C for 6 min in 7 L 
of 0.lX SSPE and 0.1% SOS in a Disk-Wisk apparatus (Schleicher 
& Schuell, Inc., Keene, NH). 
kept damp and sealed in a 
autoradiography. 
After washing, the membrane was 
plastic bag before analysis by 
VII. Filter Stripping and Reprobing 
The filters were deprobed by boiling in TE, pH 7.5, and 1% 
SOS solution for 20 to 30 min with constant stirring of the 
solution. The stripping was usually very successful if the 
filters were kept damp. 
exposing the filter to 
Complete deprobing was assured by 
an X-ray film for several days. 
Reprobing conditions were the same as for the fresh filters, 
except longer prehybridization (24 h) was usually applied to 
reduce the background. 
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VIII. Autoradiography 
The filter was either sealed in a plastic bag or covered 
with Saran wrap, then exposed to an X-ray film (X-OMAT AR, 
Eastman Kodak Co., Rochester, NY or Cronexl0, E.I. DuPont de 
Nemours & Co., Inc., Wilmington, DE) for appropriate time at -
so·c with two intensifying screens (Lightning Plus, E.I. 
DuPont de Nemours & Co., Inc.). The films were developed in 
an autoprocessor (Kodak, m35A X-OMAT Processor, Eastman Kodak, 
Rochester, NY). 
IX. cDNA Synthesis 
Total cellular Colo320HSR RNA (1 µg) was subjected to first 
strand cDNA synthesis in a solution containing 1 X PCR buffer, 
1 mM each of dCTP, dATP, dGTP, and dTTP (Perkin Elmer Cetus 
Corp., Norwalk, CT), 200 units of Moloney murine leukemia 
virus reverse transcriptase (BRL, Gaithersburg, MD), and 20 
units of RNasin (Promega, Madison, WI), 0.32 µg of oligo dT 
(BRL, Gaithersburg, MD), in a total volume of 20 µl. The 
mixture was set at room temperature for 10 min, and then 
incubated at 37°C for 1 h, heated to 95°C for 10 min and 
chilled on ice. 
X. DNA Dot Blot 
DNA dot blot is a method used to spot gene-specific probes 
on a nitrocellulose filter. Plasmid DNA containing a specific 
gene probe was linearized with the appropriate restriction 
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enzyme. Linearized plasmid DNA was denatured by 0.4 N NaOH and 
neutralized with equal volume of 2 M NH4OAc, and put on ice 
before dotting. A nitrocellulose membrane (9 X 11 cm) (0.2 
micron, Schleicher & Schuell, Inc., Keene, NH) was wetted in 
water and soaked in 1 M NH4OAc for at least 10 min. The 
presoaked membrane was sandwiched in a dot blot apparatus 
(BRL, Gaithersburg, MD). The wells were washed with 1 M 
NH4OAc twice, and then 1 µg of the linearized, denatured DNA 
plasmids was spotted into the corresponding position under 
slow vacuum. The wells were washed with 1 M NH4OAc twice. 
The filter was then labeled and carefully taken off the 
apparatus, swirled in 6 X SSC briefly, and soaked in 2 X 
Denhardt's for 15 min. The filter was sliced into strips 
while it was damp, and sandwiched between 2 pieces of 3 MM 
Whatman paper. The strips were baked under vacuum at 80 • c for 
2 h, and then stored at room temperature until hybridization. 
XI. DNA Sequencing 
DNA sequencing was carried out by using a TaqTrack system 
(Promega, Madison, WI). To label the primers (T7 and SP6) at 
their 5' ends, 10 pmol primer was incubated in a solution 
containing 10 pmol r- 32P-ATP (>3, ooo Ci/mmol), 5 units T4 
polynucleotide kinase, 50 mM Tris-HCl, pH 7.5, 10 mM MgC12 , 5 
mM DTT, 0.1 mM spermidine at 37°C for 10 min. The T4 kinase 
was inactivated by heating the reaction mixture at go•c for 2 
min. Supercoiled plasmid DNA was denatured by a 0.2 M NaOH, 
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0 . 2 mM EDTA solution for 5 min at room temperature, and 
neutralized by adding 0.2 M ammonium acetate, pH 4.6. The 
denatured DNA were pelleted and air-dried and resuspended in 
a given volume of deionized water before annealing with 32P-
end-labeled primer. After annealing, d/ddNTP mix and Tag DNA 
polymerase were added into appropriate tubes. The mixture was 
incubated at 70°C for 15 min, and the reaction stopped by 
adding appropriate amounts of 10 mM NaOH, 95% formamide, 0.05% 
bromophenol blue, 0.05% xylene cyanol and heated at 90°C for 
5 min. Half of the reaction volume was then loaded on a 6% 
polyacrylamide sequencing gel ( 2 O ml 5 X TBE, 15 ml 4 0% 
acrylamide, 25% ml dH2O, 5 g urea, 1 ml 10% APS, 20 µl TEMED). 
The gel was run at 55 W for 2 h with 1 X TBE buffer in a BRL 
sequence apparatus. The second half of the reaction was 
loaded on the gel for another two h electrophoresis. At the 
end of electrophoresis, the gel was carefully taken off the 
plates by adhering to a 3 MM Whatman paper, covered with Saran 
wrap, dried, and exposed to an X-ray film. 
Preparation of DNA probes 
I. General Information 
The genomic c-myc (pHSR-1) and c-fos (pc-fos-1) clones were 
purchased from the American Type Culture Collection 
(Rockville, MD}. The human GAPDH probe, a 400 bp fragment of 
the 5 '-flank of the GAPDH gene (-116 to -516 bp), was 
generously provided by Dr. Maria Alexander-Bridges (Harvard 
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Medical School, Boston, MA). This probe recognizes only the 
functional human GAPDH gene on a Southern blot (Ercolani et 
al., 1988). The rat GAPDH cDNA (pRGAPDH13) (Piechaczyk et 
al., 1984b; Fort et al., 1985), was supplied by Dr. Hans-
Martin Jack (Loyola University Medical Center, Maywood, IL), 
and the human B-actin gene (clone pfhBA-1) (Gunning et al., 
1983) by Dr. Richard Morimoto (Northwestern University, 
Evanston, IL). 
The probes used for detecting specific gene expression or 
gene fragment were generated either by subcloning or PCR 
amplification. The human c-myc exon 2 probe (Figure 3) is a 
414 bp PstI fragment subcloned into a pGEM-3Z vector (Promega, 
Madison, WI). The human c-myc exon 1 probe (Figure 3), a 446 
bp XhoI-PvuII fragment, was subcloned into a pGEM-3Zf (+) 
vector (Colby et al., 1983; watt et al., 1983b; Gazin et al., 
1984). The human c-fos exon 4 probe (Figure 3) was generated 
by a PCR subcloning method (Scharf, 1990). The histone H3.3 
probe was generated by PCR amplification as described in PCR 
section below. The identity of the subclones was confirmed 
either by examining the restriction enzyme digestion pattern, 
or by DNA sequencing using a TaqTrack sequencing system 
(Promega, Madison, WI). 
II. DNA Subcloning 
Subcloning was used whenever a specific gene fragment was 
in need. This technique involves several essential steps, 
c-mycexon 1 
pGEM-3Zf( +) 
c-mycexon 2 
pGEM-3Z 
c-fos exon4 
pGEM-3Zf( +) 
Pigure 3. Mapa of plasmids containing the aubcloned specific gene-fragaenta. 
Experimental details are described in Materials and Methods section. 
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including restriction enzyme digestion, gel purification of 
both insert (the desired gene fragment) and vector, BAP 
reaction, ligation, and transformation. The vector chosen for 
this study was 
(Madison, WI). 
the pGEM-3Z vector system from Promega 
PCR subcloning was applied as the alternative 
when there was no convenient restriction site available. 
A. Isolation of DNA Fragments from Agarose Gels 
Specific DNA fragments and vectors digested with 
appropriate restriction enzymes were fractionated on an 
agarose gel. After identifying the correct band, a trough was 
cut in front of the band, and a clean dialysis membrane 
(Spectra/Per membrane, Spectrum Medical Industries INC, 
Terminal Annex, LA) was shaped to fit the trough. With 
continuous electrophoresis, the DNA fragments of the correct 
size were trapped against dialysis membrane in the trough 
which filled with TE, pH 7. 5 buffer. The electrodes were 
reversed briefly (10 sec) to get the DNA fragments back into 
the trough. The DNA fragments were collected and underwent 
further purification as described above. 
B. BAP reaction 
In order to suppress self-ligation of the plasmid cloning 
vector, the restricted and purified vector was 
dephosphorylated at its 5 1 ends by treating with bacterial 
alkaline phosphatase (BAP) (BRL, Gaithersburg, MD). The 
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vector was mixed with BAP (70 U/pmol ends) in the presence of 
10 mM Tris-HCl, pH 8, heated at 65°C for 60 min. BAP was 
removed by extracting with a phenol/chloroform/isoamyl alcohol 
mixture (25:24:1) four times. 
c. Ligation 
Ends-compatible insert and vector were ligated together by 
T4 DNA ligase under the following conditions. In a total 
volume of 20 µl, 150 ng vector was mixed with insert in a 1:3 
molar ratio in the presence of 50 mM Tris-HCl, pH 7.6, 10 mM 
MgC1 2 , 1 mM ATP, 1 mM dithiothreitol, 5% (w/v) polyethylene 
glycol-8000, and 1 U T4 DNA ligase (BRL, Gaithersburg, MD). 
The ligation reaction mixture was incubated at 14-18°C for 12 
to 24 h. 
D. Transformation 
E. coli bacteria were transformed with the ligated new 
plasmids. Competent E.coli DH5a bacteria (BRL, Gaithersburg, 
MD) were removed from -80°C and thawed on ice for 15 min. The 
ligation reaction mixture was first diluted five times with TE 
buffer, then gently added into 50 µl thawed bacteria. After 
setting on ice for 30 min, the reaction was heated at 37°C for 
20 sec, and again chilled on ice for 2 min. Then 0.9 ml 
sterile LB broth without ampicillin was added and the bacteria 
allowed to grow at 37°C for 1 h in a shaking incubator (225 
rpm). Finally, the bacteria were spread out on an X-
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Gal/ampicillin agar plate ( 15 g Bacto-agar, 10 g Bacto-
tryptone, 5 g Bacto-yeast extract, 10 g NaCl, 0.8 ml of 50 
mg/ml X-gal, 5 ml of 100 mM stock IPTG, and 1 ml of 100 mg/ml 
ampicillin per liter) and incubated in a 37°C incubator for 
14-16 h to allow colony formation. The colonies were picked 
and analyzed to identify the right subclone. 
III. 32P-Labeling of Hybridization Probes 
DNA probes were made radioactive by using the random primer 
labeling method (Feinberg and Vogelstein, 1983) . In this 
method, random oligonucleotides were used to prime DNA 
synthesis in vitro by using denatured linear double-stranded 
DNA fragments as the template. Over 70% of the precursor 
triphosphate was routinely incorporated into complementary 
DNA, and specific activities of over 109 dpm/µg of DNA were 
obtained. 
The Prime-a-Gene labeling system (Promega, Madison, WI) was 
used to label gene-specific probes used in filter 
hybridization experiments. In the standard 50 µl volume 
reaction, 25 ng of gel-purified linear DNA fragments was used 
as the template. The reaction mixture contained 50 mM Tris-
HCl, pH 8, 5 mM MgC1 2 , 2 mM OTT, 1 mM HEPES, pH 6. 6, 5. 2 A260 
units/ml random hexadeoxyribonucleotides, 20 µM each of 
unlabeled dGTP, dATP, dTTP, 400 µg/ml acetylated (nuclease-
free) BSA, 50 µCi [a-32P]dCTP (3,000 Ci/mmol, Amersham, 
Arlington Heights, IL), 25 ng heat-denatured DNA fragments, 
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and 5 units Klenow enzyme. The reaction mixture was gently 
mixed and incubated at room temperature for at least 2 h or 
overnight. The unincorporated nucleotides were removed by 
size exclusion chromatography on Sephadex G-50 spin columns 
(Boehringer Manheim, Indiapolis, IN). Before the probe was 
added into the filter hybridization bag, radiolabeled DNA 
fragments were denatured by heating at 95-100°C for 5 min and 
subsequently chilling on ice. 
IV. Quantitation of 32P Incorporation 
Incorporation of 32P into DNA probes or RNA was determined 
by trichloroacetic acid (TCA) precipitable radioactivity. In 
general, nucleotides greater that 12 bp are precipitable by 
this methods. One or two percent of the labeled product was 
mixed with 25 µg yeast transfer RNA (BRL, Gaithersburg, MD) 
which served as a carrier to facilitate TCA precipitation in 
a clear Falcon tube ( 12 X 7 5 mm style, Falcon, Becton 
Dickinson and Company, Lincoln Park, NJ). After addition of 
1 ml ice cold 10% TCA, the mixture was vortexed and placed on 
ice for at least 10 min. The mixture was layered onto a 
Whatman GF/C glass fiber filter placed in a vacuum manifold 
which was prewetted with 10% TCA (Millipore, Bedford, MA). 
The tube was rinsed with cold 2% TCA and also added onto the 
filter. Lastly, the filter was washed with 95% ethanol, and 
placed in a scintillation vial. Eight ml of scintillation 
fluid (Beckman Ready Gel) were added to the vial containing 
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the filter, and the sample was counted in a Beckman Model LS 
5800 liquid scintillation counter. The percent incorporation 
of 32P in a given sample was calculated as follows: 
counts per aliquot X total volume 
% Incorporation= 
Total counts 
Polymerase Chain Reaction 
X 100 
The histone H3.3 probe was generated by using two primers 
which cover 215 bp coding region of the histone gene (Figure 
4) . The 100 µl PCR reaction is comprised of 8 µl cDNA 
synthesized from Colo320HSR total cellular RNA as described 
previously, 50 pmol each of the primers, 10 mM Tris-HCl, pH 
8.3, 50 mM KCl, 2 mM MgC1 2 , and 200 µMeach of dCTP, dATP, 
dGTP, and dTTP, two units of Taq DNA polymerase (Perkin Elmer 
Cetus, Emeryville, CA). The reaction mixture was added into 
a Genamp tube (Perkin Elmer Cetus, Norwalk, CT), and covered 
with 75 µl mineral oil (Sigma, St. Louis, MO) to prevent 
evaporation and condensation. The tube was placed in a DNA 
thermocycler (Perkin Elmer Cetus Corp., Emeryville, CA). The 
PCR reaction mixture was heated at 96°C for 5 min and then 
subjected to 30 cycles of programmed thermal cycling at 96°C 
for 30 sec; 55°C for 30 sec; and 72°C for 45 sec. After the 
completion of PCR cycling, the mineral oil was removed by 
adding an equal volume of chloroform and the PCR products were 
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Fos-lCI 
2785 2802 
5' AAGGTACCGACCTGCCTGCAAGA 3' 
Fos-EI 
3304 3287 
5' CGAATTCTGAGCGAGTCAGAGGAA 3' 
His tone H3. 3 1 
281 299 
5' CCACTGAACTTCTGATTCGC 3' 
His tone H3. 3 2 
495 478 
5' GCGTGCTAGCTGGATGTCTT 3' 
Figure 4. Nucleotide sequence of c-fos and bistone B3.3 PCR 
priaers. 
Numbering corresponds to that of human c-fos gene 
and human histone H3.3 cDNA. 
recovered by 
precipitation. 
minicolumns. 
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phenol/chloroform extraction and ethanol 
PCR products were purified further by Elutip 
To amplify c-fos exon 4, two primers (Figure 4) were 
designed to amplify 520 bp of exon-specific region which 
covers more than 80% of the c-fos exon 4 (Van Straaten et al., 
1983). Fos-KI, a 23 mer (5 1 AAGGTACCGACCTGCCTGCAAGA 3 1 ), is 
complementary to the 3' end of the coding strand of the c-fos 
gene (nt 2785-2802). The Fos-KI primer contains five non-fos-
complementary nt at its 5 1 end, which encode a recognition 
sequence for the restriction enzyme KpnI. Fos-EI, a 24 mer 
(5 1 CGAATTCTGAGCGAGTCAGAGGAA 3 1 ), is complementary to the 3 1 
end of the non-coding strand of the c-fos gene (nt 3304-3287). 
At its 5 1 end, the Fos-EI primer has six non-fos-complementary 
nt, which encode a recognition sequence for the restriction 
enzyme EcoRI. Non-fos-complementary nucleotides were included 
in the primers to facilitate subcloning of the c-fos PCR 
product into the pGEM-3Zf(+) vector. The PCR reaction for c-
fos exon 4 amplification was set up in the same condition as 
for histone H3.3 probe amplification, except 2 ng linearized 
pc-fos-1 plasmid was used as the template. Also, the reaction 
mixture was denatured at 96°C for 30 sec; reannealed at 60°C 
for 30 sec; and extended at 72°C for 1.5 min. The amplified 
PCR product was digested with KpnI and EcoRI, and then 
subcloned into the pGEM-3Zf(+) vector. 
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Northern Blot Analysis 
Northern blot analysis was used to assess specific gene 
expression at the steady state mRNA level. Briefly, an equal 
amount of total cellular RNA isolated from control or drug 
treated samples was denatured by the DMSO/glyoxal method 
(Futscher and Erickson, 1990). The denatured RNA was 
fractionated in a 1% agarose gel in a recirculating buffer 
system containing 10 mM NaPO4, pH 6. 8. After 3 h of 
electrophoresis at 100 V, the RNA was transferred to a nylon 
membrane by capillary blotting for 24 h with 10 X SSC. The 
glyoxal reaction was reversed by immersing the membrane 
sequentially with 50 mM NaOH (15 sec) and 0.2 M Tris-HCl, pH 
7.5, 2 X SSC (35 sec). The membrane was prehybridized and 
hybridized at 42°C for 24 h with a 32P-labeled probe. After 
hybridization, the blot was washed and autoradiographed. 
Subsequently, the filter was stripped and rehybridized with 
a 32P-labeled histone H3. 3 probe to monitor RNA loading 
equality. Quantitation of mRNA levels was determined by 
measuring the relative intensity of bands using scanning laser 
densitometry (LKB Ultrascan XL, LKB, Bromma, Sweden). The 
intensity of each band was expressed as the area under the 
curve (AU/mm2 ). The percentage of c-myc mRNA levels after 
drug treatment was calculated by comparing the intensity of 
the band for the drug-treated sample with that of its own time 
point control. The intensity of the band for c-myc mRNA level 
was normalized with the corresponding histone message. The 
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normalization was calculated according to the following 
formula: 
HC-HP 
AA =A+ (----
HC 
X A) 
AA: adjusted area under the curve of c-myc mRNA level; 
A: actual measured area under the curve of c-myc mRNA 
level after drug treatment; 
HC: area under the curve of hi stone message in the 
matched time point control; 
HP: corresponding area under the curve of histone 
message after drug treatment. 
Greater than 30% fluctuation in the steady state c-myc mRNA 
level is considered a significant change from baseline, based 
on the observation that the variation of mRNA levels of 
histone H3.3 gene were below 25% in northern blot analyses. 
DNA Denaturing/Renaturing Gel Electrophoresis and southern 
Blot Analysis 
This assay was developed by Vos and Hanawalt (1987) and 
modified in our laboratory (Futscher et al., 1992). The major 
steps of this assay are diagramed in Figure 5. In brief, 
after drug treatment and isolation of genomic DNA, the DNA was 
digested with the appropriate restriction enzyme at 37°C, for 
2 h. Digested DNA was resuspended in 0.01 M NaHPO4/NaH2PO4 , pH 
7. o. An equal amount of the DNA sample, either with or 
without drug treatment, was denatured by adding two volumes of 
denaturation dye (96% formamide, 1 mM EDTA, 0.1% bromphenol 
Pigure s. 
j J uM W-Pt 25 SO 100 
....,_ ds 
..- ss 
Schema for ■easuring DNA interstrand crosslinks 
in genes. 
Adapted from Futscher et al. (1992). 
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blue, 0.1% xylene cyanol), and heated at 65°C for 5 min. The 
denatured samples were quickly chilled on ice-salt slush (1 M 
cacl2 , -l0°C) and loaded onto a 0.5% neutral agarose gel. In 
addition, a non-denatured DNA sample (in 50% glycerol, 0.1% 
bromphenol blue) was also loaded on the same gel. Following 
electrophoresis at 15 volts for 18 h, the gel was treated with 
acid and alkali solutions sequentially (detailed in nucleic 
acid blotting section) to facilitate the high molecular weight 
genomic DNA transfer. After Southern blotting, the membrane 
was hybridized and washed under the same conditions for 
northern blot analysis, and then autoradiographed for 24 to 36 
h. 
The quantitation of band intensities in each lane was 
determined by Betascope scanning (Betagen Corp., Waltham, MA). 
The percentage of cross-linked DNA formed in a sample was 
determined by dividing the amount of radioactivity in the 
double-stranded DNA band (cpm) by total radioactivity detected 
in double- and single-stranded DNA bands (cpm). 
Nuclear Run-on Analysis 
The protocol used for this study was a modified version of 
Banerji's procedure (1984). The procedure was divided into 
three major steps: isolation of nuclei; labeling and 
purification of nascent RNA transcripts; and hybridization of 
labeled RNA transcripts to cDNA probes dotted onto 
nitrocellulose. 
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To isolate nuclei, cells were washed twice with 1 X ice 
cold PBS and pelleted by centrifuging at 1000 rpm (500 x g) 
(Beckman J-6M) at 4°C for 5 min. The cells were resuspended 
in lysis buffer (10 mM NaCl, 3 mM MgC1 2 , 10 mM Tris-HCl, pH 
7.4 and 0.5% NP-40) with a wide bore tip. The nuclei were 
pelleted by spinning briefly (3 sec) in a microfuge, 
resuspended in an equal volume storage buffer (0.1 mM EOTA, 5 
mM MgC12 , 50 mM Tris-HCl, pH 8 and 40% glycerol), and quickly 
frozen in ethanol:dry ice bath and stored at -80°C. 
Nascent RNA transcripts were labeled by an in vitro 
transcription reaction. An equivalent number of nuclei (- 2 
x 107 ) in 50 µl were mixed with an equal volume of 2 X 
reaction cocktail (150 mM KCl, 5 mM OTT, 5 mM MgC1 2 , 50 mM 
HEPES-KOH, 10% glycerol, 0.7 mM ATP, TTP, GTP, 0.8 µM OTP, and 
100 µCi a-[ 32P] OTP, 3000 Ci/mmol). After incubation for 30 
min at room temperature, the reactions were stopped by a 30-
min incubation with 10 o RNase-free ONase at room temperature 
followed by Proteinase K digestion (0.9 mg/ml) in the presence 
of 1.4% SOS, 4.7 M urea, 235 mM LiCl, 0.67 mM EOTA, 6.7 mM 
Tris-HCl, pH 8, 1.1 mg/ml tRNA (Sigma, St. Louis, MO) for 1 h 
at 46°C. The RNA was precipitated by adding ice cold TCA to 
a final concentration of 10%, and stored on ice for 20 min. 
The RNA was pelleted in a Hermle microcentrifuge (National 
Labnet Company, Woodridge, NJ) for 15 min and then washed with 
70% ethanol. The RNA pellets were air-dried, and resuspended 
in TE (10 mM Tris-HCl, pH 8, 1 mM EOTA) containing 0.5% SOS. 
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The resuspension of RNA was facilitated by heating the 
solution at 60°C for several hours. 
The 32P-labeled RNA was hybridized to the linearized double-
stranded cONA probes immobilized onto nitrocellulose (O. 2 
micron, Schleicher and Schuell, Inc., Keene, NH). 
Hybridization was carried out in 4.5 ml (50% formamide, 6 X 
SSC, 10 X Oenhardt's, 0.2% SOS and 50 µg/ml tRNA) for 72 hat 
42°C. The membranes were subsequently washed for 30 min in 6 
x SSC, 0.2% sos, twice for 30 min in 2 X SSC, 0.2% sos, and 
finally twice for 30 min in 0.2 X SSC, 0.2% sos at 65°C before 
autoradiography. The filter was exposed to an X-ray film for 
1 to 3 weeks. The overall RNA synthesis rates were determined 
by the amount of 32P incorporated into in vitro RNA 
transcription reactions measured by 
radioactive RNA (Sambrook et al., 1982). 
TCA precipitable 
RESULTS 
cytotoxicity studies 
To determine the biologically relevant doses for further 
studies on interactions between DNA cross-linking agents and 
gene expression, the cytotoxicities induced by either HN2 or 
cisplatin in Colo320HSR cells were determined by colony 
formation assays. As demonstrated in Figure 6, doses that 
caused 1, 2, and 3 log cell kills are 12.5, 25, and 50 µM for 
cisplatin after at least three independent experiments. HN2 
produced 1, 2, and 3 log cell kills at concentrations of 2.1, 
3.25, and 6.25 µM, respectively (Futscher and Erickson, 1990). 
The plating efficiency of Colo320HSR was 33% ± 10 (mean± SD, 
n=7). 
DNA Damage and Repair Studies 
By using DNA denaturing/renaturing gel electrophoresis and 
Southern blot analysis, the formation and removal of 
cisplatin-induced DNA interstrand cross-links were analyzed in 
a 12.5 kb EcoRI fragment that spans the three exons of the 
entire c-myc oncogene. Cisplatin-induced DNA interstrand 
cross-links formed in the c-myc gene were detectable and the 
levels of cross-links in the gene were produced in a dose-
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dependent fashion (Figure 7). The removal of DNA interstrand 
cross-links in the c-myc gene was estimated by monitoring the 
1oss of c-myc double-stranded DNA over time after drug 
treatment. Despite the difference in the initial production 
of DNA interstrand cross-links, the rate of disappearance of 
DNA interstrand cross-links induced by cisplatin in the c-myc 
gene was similar for different doses (Figures 8 and 9). 
Maximal DNA interstrand cross-links were observed immediately 
after cisplatin exposure, then gradually decreased over time. 
Detectable amounts of interstrand cross-links were still 
present 24 and 36 h after drug treatment. 
Effects of DNA Cross-linking Agents on Gene Expression studies 
To study the effects of DNA cross-linking agents on gene 
expression after either cisplatin or HN2 treatment, the 
relative transcription rates, and steady state mRNA levels of 
several genes were examined. By using nuclear run-on 
analysis, the relative transcription rates of c-myc, GAPDH, 
and B-actin genes were measured. Northern blot analysis was 
chosen to detect the steady state mRNA levels of c-myc and 
histone H3.3 genes. The c-myc oncogene is the main focus of 
the study because how an activated oncogene responds to DNA 
cross-1 inking agents is of interest. The GAPDH, hi stone H3. 3, 
and B-actin genes served as controls mainly for the validity 
of the assay. 
Figure 6. 
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survival of Colo320BSR cells following exposure 
to various concentrations of cisplatin for 1 h 
as determined by inhibition of colony formation. 
Following drug exposure, cells were seeded into 
tubes containing soft agar, and colonies were 
counted 14 days later. The percentage of 
survival was determined by dividing the number 
of colonies formed by drug-treated cells by that 
formed by control cells. Points represent the 
mean of at least 3 independent experiments, and 
bars indicate the standard deviation. 
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Figure 7. Detection of cisplatin-induced DNA interstrand 
cross-links in the c-myc oncogene immediately 
after 1 h drug exposure. 
EcoRI-digested DNA isolated from control or 
cisplatin-treated Colo320HSR cells was loaded on 
a 0.5% neutral agarose gel as either native or 
formamide-denatured samples. After 
electrophoresis, Southern blotting, and 
hybridization with the 32P-labeled c-myc probe, 
the membrane was washed and autoradiographed for 
24 to 36 h. Drug doses and positions of double-
stranded (ds) and single-stranded (ss) DNA are 
indicated. Each lane contained 10 µ,g DNA except 
the native control lane which was loaded with 5 
µ,g of DNA. 
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Figure 8. Disappearance of cisplatin-induced DNA 
interstrand cross-links formed in the c-myc 
oncogene. 
Genomic DNA was isolated from Colo320HSR cells 
immediately (0), 6, 12, 24, or 36 h after drug 
removal, then restriction digested with EcoRI. 
Equal amounts (10 µg) of DNA from mock- or drug-
treated samples were f ormamide-denatured, and 
loaded on a 0.5% neutral agarose gel, except the 
native control (5 µg). After electrophoresis, 
Southern transfer, and hybridization with the 
32P-labeled c-myc probe, the filter was exposed 
to an x-ray film for 36 to 120 h. Positions of 
double-stranded (ds) and single-stranded (ss) 
DNA are indicated. The doses (25 µM, 50 µM, and 
100 µM) used for drug treatment were indicated 
on top of each autoradiogram (Figure SA, Figure 
SB, and Figure SC). 
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Disappearance of DNA interstrand cross-links 
after cisplatin treatment in Colo320HSR cells. 
The percentage of DNA interstrand cross-links 
remaining in the c-myc gene at 6, 12, 24, and 36 
h after cisplatin exposure was determined by 
using initial cross-links (0 h) of the same dose 
as 100% control. The above graph is a 
representative result of three independent 
experiments. 
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Normal Fluctuation of c-myc mRNA 
The effects of DNA cross-linking agents {HN2 or cisplatin) 
on gene expression were examined in the Colo320HSR cell line 
which harbors an amplified and overexpressed c-myc oncogene. 
Because the expression of the c-myc oncogene can be altered by 
adding fresh serum (reviewed in Spencer and Groudine, 1991), 
normal fluctuation of c-myc mRNA levels in cells that 
underwent several changes of media, and the addition of fresh 
serum was examined. 
cells. One group 
Two groups of flasks were seeded with 
(selected at random) went through the 
identical steps of centrifugation and washing as in a drug 
treatment experiment. Another group (sham) was spun down, 
resuspended in the same medium in which the cells were grown 
(conditioned medium). Sham samples were not washed, nor was 
fresh medium added. Total cellular RNA was harvested from 
both groups at times o, 6, 12, or 24 h after mock drug 
treatment. The steady state c-myc mRNA levels were constant 
in sham samples. In cells with addition of fresh serum, the 
c-myc mRNA levels decreased at 6 and 12 hand reached normal 
levels or doubled at 24 and 36 h, respectively, when compared 
to the sham samples {Figure 10). This change in the steady 
state c-myc mRNA level was consistently observed in each 
experiment. However, no fluctuations were observed in the 
steady state levels of histone H3.3 gene in both conditions. 
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Effects of Cisplatin and HN2 on Gene Expression at the mRNA 
Level 
The effects of cisplatin or HN2 on steady state c-myc mRNA 
levels were examined by northern blot analysis. By comparing 
the steady state c-myc mRNA levels after drug treatment with 
a matched time point control, no dramatic changes were 
observed immediately after cisplatin exposure (Oh) in spite 
of different doses applied (Figure 11). The decrease in 
steady state c-myc mRNA levels was noted at 6, 12, 24, and 36 
h after 1 h cisplatin exposure, with a maximal decrease (~60%) 
occurring at 24 to 36 h. Steady state c-myc mRNA levels in 
Colo320HSR cells following 25, 50, or 100 µM cisplatin 
treatment are summarized in Table 1. 
Following HN2 treatment, the steady state c-myc mRNA levels 
were not changed immediately (0 h), but decreased at 6 and 12 
h, reaching a nadir (~70% decrease) at 24 and 36 h (Figure 
12). steady state c-myc mRNA levels after 6.25 or 12.5 µM HN2 
treatment is presented in Table 2. The decrease of c-myc 
transcripts after either cisplatin or HN2 treatment was not an 
immediate, but rather a delayed response of the cells to DNA 
cross-linking agents. 
The variability in steady state mRNA levels of histone H3.3 
after either cisplatin or HN2 treatment was less than 25% as 
measured by northern blot analysis, which served as a 
constitutively expressed control gene for equal RNA loading. 
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As shown in Figures 11 and 12, histone H3.3 gene expression 
was not affected by either drug. 
Effects of Cisplatin and HN2 on Gene Expression at the 
Transcription Level 
By nuclear run-on assays, the relative transcription rates 
of the c-myc, GAPDH, and B-actin genes after either cisplatin 
or HN2 treatment were measured. Due to the transcription rate 
difference in exon 1 and 2 of the c-myc oncogene (Bentley and 
Groudine, 1986), both exon 1 and exon 2 were spotted on the 
filter as targets. No dramatic differences in c-myc 
transcription were observed immediately after cisplatin 
treatment (Figure 13). By comparing the level of 
transcription with the matched time point control, the c-myc 
transcription rates decreased in both exon 1 and exon 2 
regions of the gene at 6, 12, and 24 h. A similar result was 
observed in cells treated with HN2 (Figure 14). 
By comparing the rate of decrease in c-myc transcription 
and mRNA level after equitoxic doses of either cisplatin or 
HN2 treatment, the suppression in c-myc transcription 
paralleled the reduced steady state levels of c-myc mRNA 
detected by northern blot analysis (Figures 15 and 16). By 24 
h after HN2 removal, c-myc transcription rates tended to 
approach normal levels as compared with those in cisplatin-
treated cells. These results suggest that the decrease in 
steady state c-myc mRNA levels produced by either HN2 or 
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cisplatin appears to be mediated, at least in part, at the 
transcriptional level. In addition, after either HN2 or 
cisplatin exposure, the reduction observed in exon 2 was 
consistently greater than that occurring at the exon 1. In 
contrast, the relative transcription rates in the GAPDH and B-
actin genes did not change dramatically after exposure to 
either drug (Figures 13 and 14). 
Total RNA Synthesis and Cell Proliferation 
Total RNA synthesis after drug treatment was estimated by 
UTP incorporation in vitro. As shown in Tables 3 and 4, the 
overall UTP incorporation did not change dramatically after 
either HN2 or cisplatin treatment, as compared to the matched 
time point control. 
Cell proliferation was monitored by electronically counting 
cells before harvesting for nuclei or nucleic acids 
preparation. In drug-treated samples, the cell concentrations 
did not change over time (Tables 5 and 6). However, cell 
concentrations in controls doubled between 24 and 36 h, in 
agreement with the doubling time of this cell line (about 24 
h) • 
Studies on Accessibility of Individual Genes to DNA Damage 
Induced by HN2. 
Early studies demonstrated that some DNA damaging agents 
interact with DNA in a heterogeneous fashion (reviewed in Bohr 
Figure 10. Changes of the steady state c-.myc lllRHA levels in 
a ■ock experiment assessed by northern blot 
analysis. 
Total cellular RNA was isolated immediately (0 
h), 6, 12, 24 and 36 h after cells were 
resuspended in fresh serum. Sham samples were 
harvested at each corresponding time. Equal 
amounts of denatured total RNA (10 µ.g) were 
loaded in each lane. After electrophoresis and 
capillary transfer, the filter was hybridized 
with 32P-labeled c-myc exon 2 probe (top panel), 
autoradiographed, then the filter was stripped 
and reprobed with a 32P-labeled histone HJ. 3 
probe and autoradiographed (bottom panel). The 
northern blot autoradiogram shown above is a 
representative of three independent experiments. 
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Figure 11. Inhibition of the steady state c-.myc llRNA levels 
following 1 h cisplatin exposure as detected by 
northern blot analysis. 
Total cellular RNA was isolated immediately (0), 
6, 12, 24, or 36 h after Colo320HSR cells were 
exposed to 25, 50, or 100 µM cisplatin or 
vehicle (control). 10 µg RNA from each sample 
was denatured, electrophoresed on a 1% agarose 
gel, transferred to a nylon membrane, and 
hybridized to a 32P-labeled c-myc probe as shown 
in the upper panel. The 2. 2-kilobase (kb) c-myc 
transcript is indicated. After stripping the 
filter, the membrane was hybridized with a 32P-
labeled hi stone H3. 3 probe. The lower panel 
shows the corresponding histone H3.3 mRNA (1.2 
kb in size) indicating equal RNA loading. The 
above figure represents three independent 
experiments. 
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Figure 12. Inhibition of the steady state c-.myc mRHA levels 
after 1 h HN2 treatment measured by northern 
blot analysis. 
The upper panel shows the decrease of the steady 
state levels of c-myc mRNA over time after 
exposing Colo320HSR cells to either vehicle or 
HN2 (6.25 or 12.5 µM). The bottom panel shows 
corresponding histone H3.3 mRNA levels 
indicating equal RNA loading. Conditions were 
the same as described in Figure 11. 
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Table 1 
zrrects or cisplatin on c-~ llRD Levels 
Time 
(h) 
0 6 12 24 36 
Dose 
(µM) 
Mean SD Mean SD Mean SD Mean SD Mean SD 
25 104 ± 19 91 ± 29 84 ± 10 60 ± 11 60 ± 16 
50 82 ± 15 71 ± 29 65 ± 11 53 ± 12 47 ± 15 
100 96 ± 18 66 ± 21 58 ± 11 41 ± 13 39 ± 32 
The change in steady state c-myc mRNA levels after cisplatin treatment (immediately 
(0), 6, 12, 24, and 36 h) is expressed as a percentage of non-drug-treated control (details 
see Materials and Methods). Mean and standard deviation of three or more experiments are 
presented. 
0) 
w 
Table 2 
arrecta or B1f2 on c-~ IIRD Levels 
Time 
(h) 
0 6 12 24 36 
Dose 
(µM) 
Mean SD Mean SD Mean SD Mean SD Mean SD 
6.25 89 ± 3 63 ± 8 36 ± 4 41 ± 7 33 ± 9 
12.50 90 ± 9 65 ± 12 54 ± 13 32 ± 9 29 ± 3 
The change in steady state c-myc mRNA levels after HN2 treatment (immediately (0), 6, 
12, 24, and 36 h) is expressed as a percentage of non-drug-treated control (details see 
Materials and Methods). Mean and standard deviation of three experiments are presented. 
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Figure 13. Nuclear run-on analysis of in 
transcription in isolated Colo320BSR 
following 1 h cisplatin exposure. 
vi'tro 
nuclei 
Nascent transcripts were 32P-labeled in nuclei 
isolated from cells immediately (0), 6, 12, or 
24 h after 50 or 100 µM cisplatin exposure, and 
hybridized to DNA probes immobilized on 
nitrocellulose. An equivalent number of nuclei 
was used in each in vitro transcription 
reaction. pBR322 vectors and pGEM-3Zf were 
included as negative controls. The filters were 
washed and autoradiographed for 1 to 3 weeks 
with an intensifying screen. 
pBR322 
pGEM-3Zf 
[ Exon I c-myc 
Exon 11 
GAPDH 
8-actin 
0 h 6 h 12 h 24 h 
C 50 100 C 50 100 C 50 100 C 50 100 
CD 
O'I 
Figure 14. Nuclear run-on analysis 
transcription in isolated 
following 1 h HN2 treatment. 
of in 
Colo320BSR 
vitro 
nuclei 
Nascent transcripts were ~P-labeled in nuclei 
isolated from cells immediately (0), 6, 12, or 
24 h after 6.25 or 12.5 µM HN2 treatment, and 
hybridized to DNA probes immobilized on 
nitrocellulose. Conditions were the same as in 
Figure 13. 
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0) 
Figure 15. comparison of c-myc transcription rates and llR.NA 
levels after 1 h cisplatin treatment. 
c-myc transcription rate relative to the matched 
time point control following 50 µ.M cisplatin 
exposure was measured by the standard nuclear 
run-on analysis, and expressed as a percentage 
(left panel). Steady state c-myc mRNA levels 
following 50 µ.M cisplatin exposure was measured 
by northern blot analysis, and expressed as a 
percent control by comparing the level of c-myc 
mRNA in drug-treated sample with that of the 
matched time point control (right panel). 
Points: mean of 3 independent experiments; Bars: 
SD. 
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Figure 16. Comparison of c-myc transcription rates and aRNA 
levels after HN2 exposure. 
Quantitation of c-myc transcription rates and 
mRNA levels following 6.25 µM HN2 treatment was 
measured by scanning densitometry, and expressed 
as a percentage as described in Figure 15. 
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Table 3 
Incorporation or a-~P-U'l'P arter cisplatin BJr:posure 
0 
Mean SD 
42 ± 5 
42 ± 17 
41 ± 15 
6 
Mean SD 
60 ± 15 
55 ± 9 
48 ± 12 
12 
Mean SD 
60 ± 9 
46 ± 10 
51 ± 6 
24 
Mean SD 
52 ± 7 
43 ± 9 
37 ± 7 
The amount of a-32P-UTP incorporated into nuclei with or without 
cisplatin treatment is expressed as 105 cpm per 107 nuclei. Mean and 
standard deviation of three independent experiments are presented here. 
Paired-t tests show that there are no differences between control and 
drug treated samples (P>0.05). 
Dose 
(µM) 
Time 
(h) 
Control 
6.25 
12.50 
Table 4 
Zncorporation of a-~P-UTP after Bll2 bp01111re 
0 
Mean SD 
38 ± 10 
27 ± 10 
23 ± 4 
6 
Mean SD 
58 ± 37 
32 ± 7 
29 ± 18 
12 
Mean SD 
37 ± 6 
34 ± 3 
31 ± 18 
24 
Mean SD 
28 ± 7 
27 ± 5 
27 ± 6 
The amount of a-32P-UTP incorporated into nuclei with or without HN2 
treatment is expressed as 105 cpm per 107 nuclei. Mean and standard 
deviation of three independent experiments are presented. Paired-t 
tests show that there are no differences between control and drug 
treated samples (P>0.05). 
Table 5 
Colo320BSR Cell concentration after Ciaplatin Bzpoaure 
Time 0 6 12 24 36 
(h) 
Dose 
(µm) 
Mean SD Mean SD Mean SD Mean SD Mean SD 
Control 4.04 ± 0.73 4.43 ± 0.67 4.70 ± 1.60 6.36 ± 0.88 8.28 ± 1.38 
25 3.16 ± 0.48 3.92 ± 1.04 4.07 ± 1.20 3.81 ± 0.58 4.74 ± 0.96 
50 3.70 ± 0.55 3.61 ± 1.09 3.63 ± 1.32 3.38 ± 0.47 3.62 ± 0.39 
100 3.69 ± 1.00 3.64 ± 0.90 3.62 ± 1.18 2.64 ± 3.17 3.72 ± 0.42 
Cell concentration ( X 105 /ml) was monitored over time after cisplatin treament. Mean 
and standard deviation of six experiments are presented. 
\0 
Ol 
Table 6 
colo320BSR Cell Concentration after Blf2 Treataent 
Time 0 6 12 24 36 
(h) 
Dose 
(µm) 
Mean SD Mean SD Mean SD Mean SD Mean SD 
Control 2.5 ± 0.7 2.7 ± 0.5 3.3 ± 0.8 4.8 ± 1.2 5.7 ± 1.2 
6.25 2.6 ± 0.9 2.8 ± 0.4 2.4 ± 0.3 1.9 ± 0.5 1.9 ± 0.7 
12.5 2.3 ± 0.8 2.4 ± 0.5 2.6 ± 0.3 2.3 ± 0.7 2.6 ± 0.8 
Cell concentration (X 105/ml) was monitored over time after HN2 treament. Mean and 
standard deviation of six experiments are presented. 
et al., 1987). 
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The accessibility of a gene to HN2 may be 
correlated with the transcriptional state of the gene by some 
indirect evidence (Wassermann et al., 1990; Futscher et al., 
1992). In this study, the formation of HN2-induced DNA 
interstrand cross-links in genes with different 
transcriptional states was evaluated. Figure 17 is the schema 
for the following groups of experiments. 
Changes in mRNA Levels of the c-myc. c-fos and GAPDH Genes in 
Colo320HSR Cells after Serum Starvation 
In search of a model to study formation of DNA interstrand 
cross-links in a gene with different transcriptional states, 
an attempt was made to up-regulate c-myc expression by serum-
starving and serum-stimulating Colo320HSR cells (Kelley et 
al., 1983; Dean et al., 1986). To our surprise, the steady 
state c-myc mRNA levels in Colo320HSR cells substantially 
decreased after addition of fresh medium, regardless of growth 
state. In exponentially growing cells, the c-myc mRNA levels 
decreased about 50-60% after fresh medium addition (Figure 
10). When shifted into fresh medium, stationary phase cells 
exhibited a deeper decrease in the c-myc mRNA levels in 
comparison with logarithmically growing cells. Figure 18 
shows a gradual decrease in the c-myc mRNA levels when cells 
underwent serum starvation for three days (Dl-D3). Cells kept 
in the stationary phase for 3 days had only 60% of the c-myc 
mRNA as compared to the exponentially growing controls. After 
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addition of fresh medium, the c-myc mRNA levels continuously 
decreased as much as 80% within several hours (Hl-H8}. 
However, 24 h after fresh medium addition, the c-myc mRNA 
levels returned to control levels (H24) . The c-fos mRNA level 
was not detectable in exponentially growing cells, but 
increased to a detectable level 1 h after fresh medium 
addition, and then gradually diminished by hour H5. The GAPDH 
mRNA levels also decreased after serum starvation and 
addition. 
The Relative Transcription Rates of Genes in Colo320HSR Cells 
In exponentially growing cells, the relative transcription 
of the c-myc, GAPDH, and B-actin genes were detectable by 
standard nuclear run-on analysis as shown in the control lane 
of Figure 19. Transcription of the c-fos gene was too low to 
be detected under the same conditions. Using an equivalent 
number of nuclei isolated from cells in logarithmically 
growing phase, or cells in stationary phase with 3-h 
conditioned or fresh medium addition, the relative 
transcription of c-myc and GAPDH decreased in cells having 
undergone serum starvation as compared to exponentially 
growing cells. When serum-starved cells were incubated in the 
conditioned medium, the relative c-myc transcription rates 
decreased by more than 50% of the exponentially growing 
control (47 ± 19, mean± SD, in exon 1 region; 35 ± 20, mean 
± SD, in exon 2 region; n=3}; whereas cells that were 
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incubated in fresh medium, c-myc transcription rates decreased 
to approximately 20% of the control (23 ± 1, mean± SD, in 
exon 1 region; 10 ± 4, mean± SD, in exon 2 region, n=3). 
These results suggest that the decrease in c-myc mRNA levels 
was mediated, at least in part, at the transcriptional level. 
surprisingly, the relative transcription rates in the 
constitutively expressed GAPDH gene, also decreased in both 
serum-starved populations. The B-actin transcription rates 
remained unchanged in cells with or without serum starvation. 
Formation of DNA Interstrand Cross-links at the Gene Level in 
Exponentially Growing Cells 
To measure the formation of DNA interstrand cross-links in 
individual genes with different transcription states, 
exponentially growing Colo320HSR cells were exposed to a 3 log 
cell kill dose of HN2 (6.25 µM) for 1 h (Futscher, 1990). By 
using DNA denaturing/renaturing gel electrophoresis and 
Southern blot analysis, the formation of DNA interstrand 
cross-links formed in c-myc, GAPDH, and c-fos gene was 
assessed (Figure 19). In the c-myc gene, approximately 15% of 
the gene copies were cross-linked following 1 h drug exposure. 
In the GAPDH gene, a single copy and highly transcribed gene, 
approximately 10% of the DNA was cross-linked after the drug 
treatment. However, in the transcriptionally silent c-fos 
gene, less than 1% of the DNA was found as cross-linked DNA. 
Thus, DNA interstrand cross-links were formed to a greater 
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extent in the two highly transcribed genes, whereas the cross-
links were minimal in a gene with a low transcription rate. 
The GC dinucleotide is a potentially cross-linkable site 
for DNA interstrand cross-links induced by HN2 (Colvin, 1982). 
Using the GCG program (Genetics Computer Group, Madison, WI), 
the frequencies of GC dinucleotides in these three genes were 
determined. 587 GC dinucleotides were found in an 8 kb 
fragment of the c-myc gene, 424 in a 6.2 kb fragment of the c-
fos gene, and 449 in a 5.4 kb fragment of the GAPDH gene. 
These three regions cover all exons of each gene, and are 
included in the restriction fragments in which HN2-induced DNA 
interstrand cross-links were measured. Overall, based on the 
GC dinucleotide content, the potentially cross-linkable sites 
are not dramatically different from one gene to another. 
Formation of DNA Interstrand Cross-links at the Gene Level in 
Cells in Stationary Phase 
As revealed by nuclear run-on analysis, c-myc transcription 
decreased in cells that underwent serum starvation and 
addition (Figure 20). After exposing cell populations with 
different c-myc transcription rates to a 3 log cell kill dose 
of HN2 (6.25 µM) for 1 h, the intensity of double-stranded DNA 
was reduced in the c-myc gene with a decreased transcription 
rate (Figure 21). Production of DNA interstrand cross-links 
in the c-myc gene decreased by 40% and 80%, respectively, in 
cells with c-myc transcription rates reduced to a similar 
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extent (Figure 22). This finding suggests that the decrease 
in formation of DNA interstrand cross-links in the c-myc gene 
paralleled the decrease in c-myc transcription rates. Similar 
findings were noted in the GAPDH gene and are presented in 
Figure 23. The amount of DNA interstrand cross-links formed 
in the GAPDH gene also correlated with its transcription 
state. DNA interstrand cross-links formed in the c-fos gene 
were minimal in cells with or without serum starvation. 
Formation of DNA Interstrand Cross-links at the Gene Level in 
Cells Treated with Hydroxyurea 
Hydroxyurea was used to down-regulate c-myc expression. 
When Colo320HSR cells were exposed to hydroxyurea for 24 h, c-
myc mRNA levels also decreased by 40% and 60% after either 1 
or 10 mM exposure, respectively (Figure 24). As demonstrated 
by nuclear run-on analysis, this decrease also was mediated at 
the transcriptional level (Figure 25). However, the amounts 
of DNA interstrand cross-links formed in the c-myc gene were 
the same in both control and HU-treated samples (Figure 26). 
The expression of the GAPDH gene did not change dramatically 
in both transcriptional and post-transcriptional levels 
(Figures 24 and 26). No changes in the formation of DNA 
interstrand-cross links in the GAPDH gene were observed. 
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Isolate Nuclear ---l►~ Nuclei Run-on Analysis 
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Pigure 17. Experimental design for studies on accessibility of a gene to DNA daaage 
induced by ID12. 
.... 
0 
"' 
103 
Figure 18. Northern blot analysis of changes in c-myc, c-
fos, and GAPDH lllRNA levels after serum 
starvation in Colo320HSR. 
Total RNA was isolated from cells in exponential 
growth phase(C), cells in stationary phase for 
1 to 3 days (designated as D1, D2, and D3), and 
stationary cells resuspended in fresh serum for 
various times (1 to 24 h, defined as Hl, H2, HJ, 
H4, HS, HS, and H24). 10 µg total RNA from each 
sample was denatured and fractionated on a 1% 
agarose gel. After northern blotting, the 
filter was first hybridized with a 32P-labeled c-
myc exon 2 probe, then stripped and hybridized 
with 32P-labeled c-fos exon 4 and mouse GAPDH 
cDNA probes sequentially. The exposure time was 
6 h for the c-myc blot, 3 days for the c-fos 
blot, and 2 days for the GAPDH blot. The sizes 
of the transcripts are indicated at the right 
side of each autoradiogram. The above figure 
shows the result of a single experiment. 
• C D1 D2 D3 H1 H2 H3 H4 HS H8 H24 
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Figure 19. Nuclear run-on analysis of in vitro transcrip-
tion in isolated Colo320BSR nuclei after serua 
starvation. 
Nuclei were isolated from cells in exponential 
growth phase (control), or cells in stationary 
phase for 3 days resuspended for 3 h in either 
conditioned medium or fresh medium. An 
equivalent number of nuclei were used for each 
in vitro transcription reaction. Nascent 32P-
labeled RNA was purified and hybridized to the 
probes immobilized on a nitrocellulose membrane. 
The filters were exposed to x-ray film for 1 
week. 
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Figure 20. Production of HN2-induced DNA interstrand cross-
links in the c-myc, c-fos, and GAPDH genes in 
exponentially growing Colo320HSR cells detected 
by DNA denaturing/renaturing gel electrophoresis 
and southern blot analysis. 
Genomic DNA was isolated from exponentially 
growing cells with 6.25 µM HN2 exposure for 1 h. 
Purified DNA was digested with either EcoRI or 
BamHI. Restricted genomic DNA was 
electrophoresed with or without formamide 
denaturation. 10 µg of genomic DNA were used in 
all lanes, except 1 µg was used for nondenatured 
control in the blot probed with 32P-labeled c-myc 
exon 2. The c-myc blot was autoradiographed for 
12 h, the GAPDH blot for 24 h, and the c-fos 
blot for 3 days. Double-stranded (ds) and 
single-stranded (ss) DNA are indicated by 
arrows. The size of ds DNA of the c-myc gene is 
12.5 kb (EcoRI digestion), the GAPDH gene 12 kb 
(BamHI digestion), the c-fos gene 9 kb (EcoRI 
digestion). 
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Figure 21. Formation of ID12-induced DNA interstrand cross-
links in the c-.myc, GAPDB, c-fos genes after 
serum starvation measured by DNA 
denaturing/renaturing gel electrophoresis and 
southern blot analysis. 
Cells in logarithmically growing phase, or cells 
in stationary phase for 3 days with 3-h 
conditioned or fresh medium addition, were 
subjected to 6.25 µM HN2 treatment for 1 h. 
Genomic DNA was isolated immediately after drug 
removal, and digested with either EcoRI or 
BamHI. 10 µg genomic DNA were loaded in each 
lane, except 1 µgin nondenatured control for 
the c-myc blot. Exposure times were 12, 24, and 
72 h for the c-myc, GAPDH, and c-fos blots, 
respectively. The probes used for each blot 
were indicated on the top of each autoradiogram. 
Double-stranded DNA (ds) and single- stranded 
(ss) DNA are as indicated by arrows. The size 
of ds DNA for each gene detected is as described 
in Figure 20. 
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Figure 22. Comparison of changes in c-myc transcription and 
DNA interstrand cross-link formation in the c-
myc gene induced by HN2 in Colo320HSR cells. 
Left panel shows the relative percentage of c-
myc transcription rates in exon 1 (open bars) 
and exon 2 (hatched bars) regions of the gene 
after serum starvation in Colo320HSR cells by 
comparison to the c-myc transcription in 
exponentially growing cells (C). CM stands for 
cells resuspended in conditioned medium, and FM 
for fresh medium. Right panel shows the 
relative percentage of DNA interstrand cross-
links in the c-myc gene in cells with different 
growth states as determined by using the percent 
formation of DNA interstrand cross-links in the 
exponentially growing cells as the reference. 
Histograms are the average of three independent 
experiments, and the standard deviation of each 
group is indicated by an error bar. The percent 
cross-links formed in the exponentially growing 
cells after 6.25 µM HN2 treatment is from 7.5% 
to 15%. 
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Figure 23. Comparison of changes in GAPDB transcription and 
DNA interstrand cross-link formation in the gene 
induced by BN2 in Colo320BSR cells. 
GAPDH transcription in cells after serum 
starvation and resuspension in either 
conditioned medium (CM) or fresh medium (FM) was 
determined by comparison to GAPDH transcription 
in exponentially growing cells (C) (left panel). 
The relative percentage of DNA interstrand 
cross-links in the GAPDH gene in cells after 
serum starvation was determined by comparison to 
the percent formation of DNA interstrand cross-
links in the exponentially growing cells as 
shown in right panel. The mean of experiments 
is indicated by the histogram, and the standard 
deviation of each group is indicated by an error 
bar. Three experiments were performed to 
determine GAPDH transcription rate, two 
experiments were done to determine HN2-induced 
DNA interstrand cross-links formed in the GAPDH 
gene. The percent formation of DNA interstrand 
cross-links in exponentially growing cells was 
from 9.4% to 11.8%. 
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Figure 24. Northern blot analysis of changes in the steady 
state c-myc lllRNA levels after hydroxyurea 
treatment. 
Total cellular RNA was isolated from cells 
treated with 1 or 10 mM hydroxyurea for 2, 12, 
or 24 h. Sham samples were set up for each 
corresponding time point. 10 µg total RNA from 
each sample was denatured and fractionated on a 
1% agarose gel. After capillary transfer, the 
membrane was hybridized with a 32P-labeled c-myc 
exon 2 probe. The autoradiogram is shown in the 
top panel. The same membrane was stripped and 
hybridized with a 32P-labeled GAPDH probe, 
indicating equal loading. 
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Figure 25. Nuclear run-on analysis of in vitro 
transcription in isolated Colo320BSR nuclei 
after hydroxyurea treataent. 
Nuclei were isolated from cells in exponential 
growth phase (Control) or cells treated with 
hydroxyurea for 24 h. An equivalent number of 
nuclei were used for each in vitro transcription 
reaction. Nascent 32P-labeled RNA was purified 
and hybridized to the probes immobilized on a 
nitrocellulose membrane. The filters were 
exposed to an x-ray film for about one week. 
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Figure 26. Production of HN2-induced DNA interstrand cross-
links in the c-myc and GAPDB genes in Colo320BSR 
cells after hydro:xyurea exposure detected by DNA 
denaturing/renaturing gel electrophoresis and 
southern blot analysis. 
Genomic DNA was isolated from cells in 
exponential growth phase, or cells preincubated 
with 1 or 10 mM hydroxyurea for 24 h, then 
treated with 6. 25 µM HN2 exposure for 1 h. 
Purified DNA was digested with either EcoRI or 
BamHI. Restricted genomic DNA was 
electrophoresed with or without denaturation. 
10 µg of genomic DNA were used in all lanes, 
except 1 µg was used for nondenatured control in 
the blot probed with 32P-labeled c-myc exon 2. 
The c-myc blot was autoradiographed for 12 h, 
the GAPDH blot for 24 h. Double-stranded (ds) 
and single-stranded (ss) DNA are indicated by 
arrows. The sizes of ds DNA of the c-myc and 
GAPDH genes detected are indicated at the right 
side of each autoradiogram. 
8tt 
t 
tn 
tn 
t 
a. ..... 
V, !'> 
(JI 
71:' 
CT 
t t 
..... 
V, a. I\) 
tn tn 71:' 
CT 
Nondenatured Control 
Denatured Control 
Control 
24 h 1 mM HU 
24 h 10 mM HU 
Nondenatured Control 
Denatured Control 
Control 
24 h 1 mM HU 
24 h 10 mM HU 
0 
I 
3 (5 
Ci) 
)> 
""'C 
0 
:::c:: 
DISCUSSION 
This dissertation has studied the relationship between DNA 
damage and repair in individual genes, and alterations of gene 
expression in response to DNA damage induced by DNA cross-
linking agents (HN2 and cisplatin) in the human tumor cell 
line Colo320HSR. These two DNA cross-1 inking agents were 
found capable of not only producing DNA interstrand cross-
links in the c-myc oncogene, but also decreasing steady state 
c-myc mRNA levels at the transcriptional level. In addition, 
some evidence indicates that the accessibility of a gene to 
HN2-induced DNA interstrand cross-links may be determined by 
the transcriptional state of the gene. 
DNA Interstrand Cross-link Formation and Disappearance in 
Individual Genes 
Previously, studies of DNA cross-linking produced by HN2 
and cisplatin were only possible at the genomic level. With 
the advent of molecular biologic techniques, it became 
possible to study DNA interstrand cross-links at the gene 
level (Vos and Hanawalt, 1987). Cisplatin-induced DNA 
interstrand cross-links in the genome were detectable by 
treating cells with a dose as low as 1 µM (Zwelling et al., 
119 
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1978). In order to detect cisplatin-induced DNA interstrand 
cross-links in specific genomic regions, a dose as high as 200 
µM was used in a cell line in which only 9.5 µM of cisplatin 
was needed to kill 50% of the cells (Jones et al., 1991). 
Using a modification of the original method (Futscher et al., 
1992), DNA interstrand cross-links produced by cisplatin were 
detectable in the c-myc oncogene when Colo320HSR cells were 
exposed to a dose as low as 25 µM (produces a 2 log cell kill) 
in this study. This result indicates that cisplatin-induced 
interstrand cross-links can be detected at the gene level at 
biologically relevant doses. 
The kinetics of formation and disappearance of cisplatin-
induced interstrand cross-links at the gene level are similar 
to those noted in the overall genome with the exception that 
maximal cross-links occourred immediately (0 h) after one hour 
drug treatment. Using the alkaline elution technique, DNA 
interstrand cross-1 inks were maximal at 6 to 12 h after 
cisplatin treatment in the whole genome, and the majority 
disappeared by 24 h (Zwelling et al., 1978, 1979 and 1981). 
As shown in Figure 8, interstrand cross-links induced by 
cisplatin in the c-myc gene were maximal immediately (Oh) 
after drug treatment despite the dose difference. DNA 
interstrand cross-links disappeared over time with the 
majority of them removed by 24 hours as depicted in Figure 9. 
It is possible that cisplatin-induced DNA interstrand cross-
links in the c-myc oncogene formed much more rapidly than 
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those in the overall genome. However, the time needed for 
isolation of DNA from drug treated cells was about 16 to 18 
hours in the DNA denaturing/renaturing gel electrophoresis 
assay used for detecting interstrand cross-links in a specific 
genomic region. This situation is similar to the conditions 
used in the experiments done by D'Incalci et al. (1985), who 
showed that cisplatin induced cross-links continued to form up 
to 24 h after lysis of cells on a membrane filter which was 
incubated at pH 10, and 37°C. It seems more likely that 
continued formation of cisplatin cross-links in the process of 
DNA isolation contributes to the maximal cross-links formed at 
0 h. 
Disappearance of cisplatin cross-links in the c-myc gene 
occurred as early as 6 h after drug treatment. 12 h after 
drug treatment, about 50% of the cross-links were removed. 
These data are in contrast to those noted in the overall 
genome, in which cisplatin cross-links peaked at 12 h after 
drug treatment (Zwelling et al., 1978 and 1979). This finding 
suggests that cisplatin-induced DNA interstrand cross-links 
may be preferentially repaired from the actively transcribed 
c-myc oncogene, which is consistent with the notion that DNA 
damage is repaired faster in actively transcribed genes as 
compared to DNA repair in the overall genome (Bohr et al., 
1985) . 
In similar experiments, HN2-induced DNA interstrand cross-
links disappeared by 6 h after drug treatment in the c-myc 
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gene in Colo320HSR cells (Futscher et al., 1992). These data 
suggest that similar types of DNA lesions may pose a different 
challenge to cells, triggering different cellular repair 
processes. 
suppression of c-myc mRNA Expression Mediated at the 
Transcriptional Level 
C-myc mRNA levels decreased substantially in Colo320HSR 
after either HN2 or cisplatin exposure, while overall RNA 
synthesis was not changed. The steady state c-myc mRNA level 
was not reduced immediately after exposing cells to either 
drug, but decreased at 6 hand gradually reached its nadir at 
24 and 36 h. In addition, nuclear run-on analysis revealed 
that the decrease in c-myc mRNA levels was mediated, at least 
in part, at the transcriptional level. The delayed decrease 
in c-myc expression suggests that the suppression is a 
secondary response to either drug rather than a direct 
consequence of DNA lesions formed in the gene. 
The inhibition of c-myc transcription may be caused by 
several mechanisms. Maximal DNA inters tr and cross-1 inks 
produced by either drug were observed immediately after drug 
treatment, while the inhibition of c-myc transcription at this 
point was minimal. This observation suggests that the 
inhibition of c-myc expression is most likely an indirect 
response to DNA damage produced by these drugs. It is 
possible that the decrease in c-myc transcription was caused 
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by a specific cellular process triggered by DNA lesions 
produced by the drug. Lippard and colleagues have reported 
recently that cisplatin adducts could bind to the high-
mobility group protein, HMGl (Piland Lippard, 1992). HMGl 
has been identified as a possible general transcription factor 
(Singh and Dixon, 1990). The suppression of c-myc expression, 
therefore, may be a consequence of inhibition of transcription 
factors. In addition, extensive evidence has indicated that 
the constantly high levels of c-myc expression in 
proliferating cells would decrease when cells escape from the 
cell cycle and undergo terminal differentiation (Kelly et al. , 
1983: Campisi et al., 1984: Simpson et al., 1987: Siebenlist 
et al. , 1988) . The suppression of c-myc transcription, 
alternatively, may be caused by a general response to 
inhibition of cell multiplication. 
The possibility that the inhibition of c-myc transcription 
is partly due to a direct consequence of DNA lesions produced 
by either drug on the DNA template, however, cannot be 
completely excluded. As revealed by nuclear run-on analysis, 
the extent of decrease of c-myc transcription at exon 2 was 
greater than that at exon 1. This finding implies that 
transcription elongation may be blocked by the damage on the 
DNA template, or the termination of c-myc transcripts at the 
end of exon 1 may be increased after drug treatment. 
Suppression of c-myc expression at the mRNA level may be 
caused by inhibition of c-myc transcription initiation, 
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increased termination of c-myc transcripts, and/or blockage of 
transcription elongation by DNA adducts. 
A recent study has shown that expression of c-myc protein 
is required to induce apoptosis (a genetically programmed form 
of cell death) in fibroblasts when cells were grown in low 
serum (Evan et al. 1992). Perturbation in c-myc expression 
may initiate a cell death program. It would be worthwhile to 
find out the expression level of c-myc protein in cells after 
cisplatin or HN2 exposure. Anti-tumor agents, like cisplatin 
and HN2, may trigger the cell death pathway by disturbing c-
myc protein expression in cells. 
studies on the Accessibility of a Gene to HN2-induced DNA 
Interstrand cross-linking Damage 
Consistent with previous findings that HN2-induced DNA 
alkylation adducts and DNA interstrand cross-links are 
heterogeneously distributed in different sub-genomic regions 
(Wassermann et al., 1990; Futscher et al., 1992), HN2-induced 
DNA interstrand cross-links formed preferentially in highly 
transcribed genes in Colo320HSR cells. It is generally 
accepted that actively transcribed genes that are temporarily 
dissociated from nucleosome particles are more accessible to 
DNA damage induced by various agents than inactive DNA (Bohr 
et al., 1987). This study presents direct evidence which 
correlates the transcriptional activity of a gene with its 
accessibility to HN2-induced DNA damage. In the c-fos gene, 
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a transcriptionally inactive gene, the formation of DNA 
interstrand cross-links was minimal, and could be a result of 
transient activation of the c-fos gene induced by HN2 
(Futscher and Erickson, 1990; Hollander and Fornace, 1989). 
However, in the transcriptionally active c-myc and GAPDH 
genes, whose transcription rates were high enough to be 
detected by standard nuclear run-on assays, substantial 
amounts of DNA inters tr and cross-1 inks were found in each 
gene. Moreover, when c-myc gene expression was down regulated 
by serum starvation and addition at the transcriptional level, 
the production of HN2-induced DNA interstrand cross-links in 
the gene decreased parallel to c-myc suppression. The same 
also was true with the GAPDH gene. When GAPDH gene 
transcription was decreased, the amounts of DNA interstrand 
cross-links formed in the gene were also reduced. These 
results are in agreement with the notion that 
transcriptionally active genes have a more open conformation 
than transcriptionally inactive genes and are more susceptible 
to DNA damage. 
Unfortunately, complete nucleotide sequences of the entire 
DNA fragments probed are not available for analyzing 
potentially cross-linkable sites. No substantial differences, 
however, have been found when comparing GC dinucleotide 
frequencies existing in the regions that span all exons in 
each gene. The possibility that the differences in production 
of DNA interstrand cross-links are due to the differences in 
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potentially cross-linkable sites in these genes is very 
unlikely. 
In contrast, no changes in the amounts of DNA interstrand 
cross-linking produced in the c-myc gene were observed when 
the gene was down-regulated at the transcriptional level by 
hydroxyurea. This result is puzzling because presumably when 
a gene is not actively transcribed, it exists in a condensed 
form associated with basic histone proteins. A gene in the 
condensed chromatin would be less accessible to DNA damage 
induced by drugs. As we know, hydroxyurea inhibits DNA 
synthesis by depleting the pool of deoxyribonucleoside 
triphosphate (Bianchi et al., 1986; Collins and Oates, 1987). 
It is possible that the chromatin structure is decondensed in 
the genome after hydroxyurea treatment. If this is the case, 
the c-myc gene may remain accessible to DNA damage induced by 
nitrogen mustard, even though the c-myc expression is 
suppressed. 
Regulation of c-myc and GAPDH Gene Expression 
Regulation of c-myc gene expression is a complicated 
cellular process as revealed by numerous studies (Spencer and 
Groudine, 1991; Cole, 1986; Kelly, 1986). c-myc proto-
oncogene expression is regulated by stimuli that control cell 
growth. Growth-promoting agents generally induce c-myc 
expression, whereas growth-inhibiting agents often result in 
a decrease of c-myc expression. For instance, growth 
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stimulation of quiescent cells by serum elevates expression of 
the c-myc proto-oncogene up to 10 to 40 fold in Balb/c3T3 
(A31) cells (Campisi et al., 1984). In two chemically 
transformed A31 derivatives, however, c-myc expression is 
constitutive (Campisi et al., 1984) . c-myc expression in 
Colo320HSR cells did not increase after serum addition as 
expected, which may be a cell-specific phenomenon. 
Furthermore, an aberrant response to growth stimuli in a cell 
line, which harbors an amplified and overexpressed c-myc 
oncogene is not totally unexpected (Ali talo et al. , 1983; 
Schwab et al., 1986). 
The GAPDH gene has been widely used as a constitutively 
expressed control in gene expression studies (Blanchard et 
al., 1985; Laird-Offringa et al., 1990; Pei and Calame, 1988; 
Gringnani et al., 1990; Penn et al., 1990). GAPDH was chosen 
in this study as the constitutive gene, but it failed to serve 
as a constitutively expressed control in the serum starvation 
and addition experiments. This is not totally unexpected for 
enhanced expression of the GAPDH gene has been found in some 
tumor cell lines (Tokunaga et al., 1987; Schek et al., 1988; 
Persons et al., 1989), and its expression can be altered by 
many stimuli, such as insulin, interleukin 2, and a calcium 
ionophore (Alexander et al., 1985 and 1988; Sabath et al., 
1990; Chao et al., 1990). Furthermore, in quiescent rat 
fibroblasts, GAPDH mRNA levels increase as a result of 
stimulation with EGF or serum (Matrisian et al., 1985). After 
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all, there is probably no universal constitutively expressed 
gene. 
In summary, this study has attempted to elucidate the 
relationship between DNA cross-linking agents and gene 
expression. HN2 and cisplatin produced DNA interstrand cross-
links in the c-myc gene and inhibited c-myc gene expression. 
However, HN2-induced DNA interstrand cross-links were found in 
the GAPDH gene, but no dramatic decrease in GAPDH gene 
transcription were observed. In addition, when the production 
of HN2-induced DNA interstrand cross-links in the same gene or 
different genes of different transcriptional states were 
measured, the amounts of cross-links formed in the gene were 
dependent on the rate of transcription, indicating that the 
accessibility of a gene to HN2-induced DNA interstrand cross-
links is correlated with its transcriptional state. 
Overall, this study shows that DNA interstrand cross-
linking agents like HN2 and cisplatin can produce cross-links 
in highly transcribed genes, but DNA interstrand cross-links 
may not necessarily suppress gene expression. This finding 
indicates that inhibition of certain gene expression by DNA 
cross-linking agents is not a direct consequence of DNA 
lesions themselves, but rather represents an overall cellular 
response to these agents. Inhibition of critical gene 
expression like that of c-myc may prevent cells from 
proceeding through the cell cycle or may trigger cell death 
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pathways, thereby contributing to the cytotoxicity induced by 
these agents. 
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